US624012A
(en)
|
|
1899-05-02 |
|
Stenciling or decorative device |
US568822A
(en)
|
|
1896-10-06 |
|
Lamp-wick and art of producing same |
US482828A
(en)
|
|
1892-09-20 |
|
Locomotive |
AU527784B2
(en)
|
1978-05-26 |
1983-03-24 |
Bang, Hans Olaf Dr. |
Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
|
JPS57112593A
(en)
|
1980-12-26 |
1982-07-13 |
Koken Boring Machine Co |
Lathe drill
|
US4377526A
(en)
|
1981-05-15 |
1983-03-22 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid and its esters
|
US4526902A
(en)
|
1983-10-24 |
1985-07-02 |
Century Laboratories, Inc. |
Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
|
CA1239587A
(en)
|
1983-10-24 |
1988-07-26 |
David Rubin |
Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
|
US4745127A
(en)
|
1983-10-31 |
1988-05-17 |
Merck Frosst Canada, Inc. |
Benzyl esters of benzofuran-2-carboxylic acids useful as inhibitors of leukotriene biosynthesis
|
US4663347A
(en)
|
1983-10-31 |
1987-05-05 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
|
US4933351A
(en)
|
1983-10-31 |
1990-06-12 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carbox amides useful as inhibitors of leukoriene biosynthesis
|
US4822803A
(en)
|
1983-10-31 |
1989-04-18 |
Merck Frosst Canada, Inc. |
Benzofuran 2-carboxylic acid hydrazides useful as inhibitors of leukotriene biosynthesis
|
US4673684A
(en)
|
1984-04-04 |
1987-06-16 |
Terumo Corporation |
Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
|
JPS6135356A
(ja)
|
1984-07-27 |
1986-02-19 |
Nippon Oil & Fats Co Ltd |
血液脂質脂肪酸の分析方法
|
US4728735A
(en)
|
1984-10-15 |
1988-03-01 |
Merck & Co., Inc. |
10,11-dihydro-dibenzo-[b,f][1,4]-thiazepin derivatives
|
GB8505285D0
(en)
|
1985-03-01 |
1985-04-03 |
Beecham Group Plc |
Compounds
|
US4624964A
(en)
|
1985-03-27 |
1986-11-25 |
E. I. Du Pont De Nemours And Company |
Aryl oxo-alkynoates as 5-lipoxygenase inhibitors
|
SU1600627A3
(ru)
|
1985-05-08 |
1990-10-15 |
Е.И.Дюпон Де Немур Энд Компани (Фирма) |
Способ получени 2-замещенных 1-нафтолов
|
US5008390A
(en)
|
1985-05-23 |
1991-04-16 |
Smithkline Beckman Corporation |
Compounds for preparing 6-phenyl-2,3-dihydroimidazo[2,1-b]-thiazoles and corresponding thiazines
|
US4803279A
(en)
|
1985-05-23 |
1989-02-07 |
Smithkline Beckman Corporation |
1.4-dihydro-4-pyridyl-substituted imidazo (2,1-b) thiazoles and the corresponding thiazines.
|
US4786755A
(en)
|
1985-06-03 |
1988-11-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
US4602023A
(en)
|
1985-06-03 |
1986-07-22 |
Warner-Lambert Company |
Diphenic acid monoamides
|
GB8515522D0
(en)
|
1985-06-19 |
1985-07-24 |
Beecham Group Plc |
Compounds
|
EP0347509A1
(en)
|
1988-06-21 |
1989-12-27 |
Century Laboratories Inc. |
A process of extraction and purification of polyunsaturated fatty acids from natural sources
|
US4939169A
(en)
|
1985-09-20 |
1990-07-03 |
The Upjohn Company |
1,4-naphthalenediol and 1,4-hydroquinone derivatives
|
JPS63501288A
(ja)
|
1985-09-20 |
1988-05-19 |
ジ・アップジョン・カンパニ− |
1,4−ナフタレンジオ−ルおよび1,4−ヒドロキノン誘導体
|
JPS6272657A
(ja)
|
1985-09-27 |
1987-04-03 |
Terumo Corp |
アミド誘導体およびこれを含有する5−リポキシゲナ−ゼ作用阻害剤
|
US4694018A
(en)
|
1985-11-29 |
1987-09-15 |
G. D. Serale & Co. |
Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
|
US4847270A
(en)
|
1985-12-12 |
1989-07-11 |
Smithkline Beckman Corporation |
Inhibition of the 5-lipoxygenase pathway utilizing certain 2,2'-alkyldiyl bis(thio)bis-imidazoles and derivatives
|
US4719218A
(en)
|
1985-12-12 |
1988-01-12 |
Smithkline Beckman Corporation |
Pyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitor
|
US4728656A
(en)
|
1985-12-12 |
1988-03-01 |
Smithkline Beckman Corporation |
2,2-alkyldiylbis(thio)bis(imidazoles) useful for inhibition of the 5-lipoxygenase pathway
|
US4686231A
(en)
|
1985-12-12 |
1987-08-11 |
Smithkline Beckman Corporation |
Inhibition of 5-lipoxygenase products
|
US5134150A
(en)
|
1985-12-12 |
1992-07-28 |
Smithkline Beecham Corporation |
Inhibition of the 5-lipoxygenase pathway
|
US4751310A
(en)
|
1985-12-12 |
1988-06-14 |
Smithkline Beckman Corporation |
Inhibition of the 5-lipoxygenase pathway
|
US4711903A
(en)
|
1986-01-31 |
1987-12-08 |
G. D. Searle & Co. |
Phenolic thioethers as inhibitors of 5-lipoxygenase
|
US4755524A
(en)
|
1986-01-31 |
1988-07-05 |
G. D. Searle & Co. |
Novel phenolic thioethers as inhibitors of 5-lipoxygenase
|
IE59813B1
(en)
|
1986-05-09 |
1994-04-06 |
Warner Lambert Co |
Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
|
US4794114A
(en)
|
1986-08-19 |
1988-12-27 |
Smithkline Beckman Corporation |
Inhibition of interleukin-1 production by monocytes and/or macrophages
|
US4672075A
(en)
|
1986-08-26 |
1987-06-09 |
E. R. Squibb & Sons |
7-Oxabicyclo(2.2.1)heptane hydroxamic acid derivatives useful as antiinflammatory, antiasthma and antipsoriatic agents
|
US4920098A
(en)
|
1986-09-17 |
1990-04-24 |
Baxter International Inc. |
Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
|
US4695585A
(en)
|
1986-09-23 |
1987-09-22 |
E. R. Squibb & Sons, Inc. |
7-oxabicyclo(2.2.1)heptane analogs useful as inhibitors of 5-lipoxygenase and cyclooxygenase
|
US4695586A
(en)
|
1986-09-23 |
1987-09-22 |
E. R. Squibb & Sons, Inc. |
7-oxabicyclo(2.2.1)heptane-based derivatives useful as antiinflammatory, antiasthma and antipsoratic agents
|
CA1321767C
(en)
|
1986-12-26 |
1993-08-31 |
Noriko Okazaki |
Process for production of eicosapentaenoic acid
|
US4861798A
(en)
|
1986-12-29 |
1989-08-29 |
Bristol-Myers Company |
Lipoxygenase inhibitory compounds
|
US4731382A
(en)
|
1986-12-29 |
1988-03-15 |
Bristol-Myers Company |
Lipoxygenase inhibitory phenylalkanohydroxamic acids
|
JPS63185390A
(ja)
|
1987-01-27 |
1988-07-30 |
Suntory Ltd |
藻類によるエイコサペンタエン酸の製造方法
|
US5250565A
(en)
|
1987-02-10 |
1993-10-05 |
Abbott Laboratories |
Indole-,benzofuran-,and benzothiophene-containing lipoxygenase-inhibiting compounds
|
US4877881A
(en)
|
1987-04-06 |
1989-10-31 |
Warner-Lambert Company |
Process of preparing pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxygenase inhibitors
|
US4889941A
(en)
|
1987-04-23 |
1989-12-26 |
Fisons Corporation |
Synthetic flavonoids as inhibitors of leukotrienes and 5-lipoxygenase
|
US5252333A
(en)
|
1987-04-27 |
1993-10-12 |
Scotia Holdings Plc |
Lithium salt-containing pharmaceutical compositions
|
US5162365A
(en)
|
1987-05-07 |
1992-11-10 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
US4801611A
(en)
|
1987-05-07 |
1989-01-31 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
US5036105A
(en)
|
1987-05-07 |
1991-07-30 |
G. D. Searle & Co. |
5-lipoxygenase inhibitors
|
GB8711802D0
(en)
|
1987-05-19 |
1987-06-24 |
Fujisawa Pharmaceutical Co |
Dithioacetal compounds
|
US4835189A
(en)
|
1987-06-05 |
1989-05-30 |
G. D. Searle & Co. |
Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
|
US4835190A
(en)
|
1987-06-05 |
1989-05-30 |
G. D. Searle & Co. |
Phenolic thioethers as inhbitors of 5-lipoxygenase
|
US5198468A
(en)
|
1987-06-24 |
1993-03-30 |
Efamol Holdings Plc |
Essential fatty acid composition
|
US4970210A
(en)
|
1987-07-17 |
1990-11-13 |
Abbott Laboratories |
Triazinone lipoxygenase compounds
|
US5086052A
(en)
|
1987-07-17 |
1992-02-04 |
Abbott Laboratories |
Substituted 1,4,5,6-tetrahydro-2H-pyridazin-3-one and -3-thione compounds having lipoxygenase inhibitory activity
|
US4843095A
(en)
|
1987-08-07 |
1989-06-27 |
Century Laboratories, Inc. |
Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
|
FR2621038B1
(fr)
|
1987-09-28 |
1989-12-29 |
Rhone Poulenc Sante |
Derives d'alcadienes, leurs preparations, les medicaments les contenant et produits intermediaires
|
US5130483A
(en)
|
1987-10-16 |
1992-07-14 |
Terumo Kabushiki Kaisha |
Isoprenoid derivatives and pharmaceutical preparations containing the same
|
US5059609A
(en)
|
1987-10-19 |
1991-10-22 |
Pfizer Inc. |
Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
|
US6166031A
(en)
|
1987-10-19 |
2000-12-26 |
Pfizer Inc, |
Substituted tetralins, chromans and related compounds in the treatment of asthma
|
CA1334975C
(en)
|
1987-11-13 |
1995-03-28 |
James H. Holms |
Furan and pyrrole containing lipoxygenase inhibiting compounds
|
JPH01149764A
(ja)
|
1987-12-07 |
1989-06-12 |
Green Cross Corp:The |
ビス−s−アルキルベンゼン誘導体
|
CA1331757C
(en)
|
1988-02-29 |
1994-08-30 |
Janssen Pharmaceutica Naamloze Vennootschap |
5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
|
US4943587A
(en)
|
1988-05-19 |
1990-07-24 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
|
US5112868A
(en)
|
1988-05-19 |
1992-05-12 |
Warner-Lambert Company |
Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues having cyclooxygenase and 5-lipoxygenase inhibition
|
US5354768A
(en)
|
1988-07-26 |
1994-10-11 |
Sankyo Company, Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5665752A
(en)
|
1988-07-26 |
1997-09-09 |
Sankyo Company, Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5232939A
(en)
|
1988-07-26 |
1993-08-03 |
Sankyo Company Limited |
Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents
|
US5260294A
(en)
|
1988-08-09 |
1993-11-09 |
Hoffman-La Roche Inc. |
Chromanes and their pharmaceutical compositions and methods
|
GB8819110D0
(en)
|
1988-08-11 |
1988-09-14 |
Norsk Hydro As |
Antihypertensive drug & method for production
|
CA1338683C
(en)
|
1988-09-13 |
1996-10-29 |
Efamol Holdings Plc |
Fatty acid therapy and compositions
|
GB2223943A
(en)
|
1988-10-21 |
1990-04-25 |
Tillotts Pharma Ag |
Oral disage forms of omega-3 polyunsaturated acids
|
US5066658A
(en)
|
1988-11-10 |
1991-11-19 |
Ortho Pharmaceutical Corporation |
Substituted hydroxyureas
|
US5155122A
(en)
|
1988-11-29 |
1992-10-13 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
|
US5256680A
(en)
|
1988-11-29 |
1993-10-26 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
|
US5068251A
(en)
|
1988-12-16 |
1991-11-26 |
Abbott Laboratories |
Lipoxygenase inhibiting compounds
|
US4935243A
(en)
|
1988-12-19 |
1990-06-19 |
Pharmacaps, Inc. |
Chewable, edible soft gelatin capsule
|
US5234950A
(en)
|
1988-12-23 |
1993-08-10 |
Imperial Chemical Industries Plc |
Tetrahydrofuran derivatives
|
IL92620A0
(en)
|
1988-12-23 |
1990-08-31 |
Ici Pharma |
Cycloalkane derivatives
|
US5229386A
(en)
|
1989-01-05 |
1993-07-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
|
US5145860A
(en)
|
1989-01-05 |
1992-09-08 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds and pharmaceutical composition comprising the same
|
US5217971A
(en)
|
1989-01-05 |
1993-06-08 |
Fujisawa Pharmaceutical Co., Ltd. |
Thiazole compounds and pharmaceutical composition comprising the same
|
JP2839276B2
(ja)
|
1989-01-23 |
1998-12-16 |
日本分光工業株式会社 |
超臨界流体抽出・分離方法及び装置
|
US5217977A
(en)
|
1989-02-28 |
1993-06-08 |
Imperial Chemical Industries Plc |
Heterocyclic cycloalkanes
|
GB8906369D0
(en)
|
1989-03-20 |
1989-05-04 |
Tisdale Michael J |
Eicosapentaenoic acid
|
US5457130A
(en)
|
1989-03-20 |
1995-10-10 |
Cancer Research Campaign Technology Limited |
Eicosapentaenoic acid used to treat cachexia
|
US5298512A
(en)
|
1989-04-07 |
1994-03-29 |
Pfizer Inc. |
Substituted chromans and their use in the treatment of asthma, arthritis and related diseases
|
WO1990012006A1
(en)
|
1989-04-07 |
1990-10-18 |
Pfizer Inc. |
Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma, arthritis and related diseases
|
US5300655A
(en)
|
1989-04-18 |
1994-04-05 |
Pfizer Inc. |
2-carboxy-thiophene derivatives
|
US5047554A
(en)
|
1989-04-18 |
1991-09-10 |
Pfizer Inc. |
3-substituted-2-oxindole derivatives
|
US5006549A
(en)
|
1989-05-24 |
1991-04-09 |
Merck & Co., Inc. |
Novel 7-aroyl-4-hydroxy-3-methyl-benzofurans as dual inhibitors of cyclooxygenase and 5-lipoxygenase
|
US5066668A
(en)
|
1989-06-09 |
1991-11-19 |
Warner-Lambert Co. |
Triazole derivatives of fenamates as antiinflammatory agents
|
US4962119A
(en)
|
1989-06-09 |
1990-10-09 |
Warner-Lambert Company |
Triazole derivatives of fenamates as antiinflammatory agents
|
US5384318A
(en)
|
1989-06-22 |
1995-01-24 |
Pfizer Inc. |
Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
|
ES2057415T3
(es)
|
1989-07-26 |
1994-10-16 |
Ici Plc |
Derivados biciclicos.
|
US4978679A
(en)
|
1989-09-25 |
1990-12-18 |
Merck & Co., Inc. |
6- and/or 7-substituted-1,2,3,4,4A,9B-hexahydro-8-hydroxydibenzofuran-3-ols as inhibitors of leukotriene biosynthesis
|
US4975457A
(en)
|
1989-09-25 |
1990-12-04 |
Merck & Co., Inc. |
Trans 2,3-disubstituted-2,3-dihydro-5-hydroxy-benzofurans as inhibitors of leukotriene biosynthesis
|
GB9018134D0
(en)
|
1989-09-29 |
1990-10-03 |
Ici Plc |
Heterocyclic derivatives
|
JPH03148217A
(ja)
|
1989-11-02 |
1991-06-25 |
Terumo Corp |
フエノキシプロピルアミン誘導体またはその塩ならびにこれらを含有する抗潰瘍剤
|
US5504108A
(en)
|
1990-01-12 |
1996-04-02 |
The Ohio State University Research Foundation |
Optically pure 4-aryl-2-hydroxytetronic acids
|
US5093356A
(en)
|
1990-01-16 |
1992-03-03 |
Merck Frosst Canada, Inc. |
Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
|
US5036067A
(en)
|
1990-03-14 |
1991-07-30 |
Merck & Co., Inc. |
Dibenzoheterocyclic hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
|
US5086064A
(en)
|
1990-03-27 |
1992-02-04 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and imidazolyl methanones and related compounds as antiinflammatory agents
|
US5102897A
(en)
|
1990-03-27 |
1992-04-07 |
Warner-Lambert Company |
3,5-ditertiarybutyl-4-hydroxyphenyl, 1,3,4-thiadiazoles and oxadiazoles linked by carbon, oxygen, and sulfur residues
|
US5234937A
(en)
|
1990-03-27 |
1993-08-10 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxphenyl oxazolyl methanones and related compounds as antiinflammatory agents
|
US5234939A
(en)
|
1990-03-27 |
1993-08-10 |
Warner-Lambert Company |
3,5-di-tertiary-butyl-4-hydroxyphenyl imidazolyl methanones and related compounds as antiinflammatory agents
|
US5143928A
(en)
|
1990-03-27 |
1992-09-01 |
Warner-Lambert Company |
3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
|
DK95490D0
(da)
|
1990-04-18 |
1990-04-18 |
Novo Nordisk As |
Fremgangsmaade til fremstilling af triglycerid og triglyceridsammensaetning
|
HUT65614A
(en)
|
1990-04-30 |
1994-07-28 |
Isis Pharmaceuticals Inc |
Process for the oligonucleotide modulation of arachidonic acid metabolism
|
CA2043615C
(en)
|
1990-06-04 |
2001-08-14 |
Kazuhiko Hata |
Method of producing eicosapentaenoic acid or the ester derivative thereof
|
GB9012651D0
(en)
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
IE911919A1
(en)
|
1990-06-21 |
1992-01-01 |
Zeneca Ltd |
Bicyclic heterocyclic compounds
|
IE911853A1
(en)
|
1990-06-21 |
1992-01-01 |
Ici Plc |
Heterocyclene derivatives
|
US5254581A
(en)
|
1990-06-21 |
1993-10-19 |
Imperial Chemical Industries Plc |
Pyran derivatives and their use as inhibitors of 5-lipoxygenase
|
US5064851A
(en)
|
1990-07-24 |
1991-11-12 |
Pfizer Inc. |
3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
|
CA2088503A1
(en)
|
1990-09-07 |
1992-03-08 |
Richard August Mueller |
Phenolic thioetheramides as 5-lipoxygenase inhibitors
|
JPH04134077A
(ja)
|
1990-09-21 |
1992-05-07 |
Taiho Yakuhin Kogyo Kk |
イソオキサゾール化合物
|
US5811432A
(en)
|
1990-11-09 |
1998-09-22 |
Pfizer Inc |
Azaoxindole derivatives
|
JP3103588B2
(ja)
|
1990-11-16 |
2000-10-30 |
持田製薬株式会社 |
リポプロテイン(a)低下剤
|
US5248682A
(en)
|
1991-01-31 |
1993-09-28 |
Warner-Lambert Company |
2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
US5177079A
(en)
|
1991-01-31 |
1993-01-05 |
Warner-Lambert Company |
2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
EP0505122A1
(en)
|
1991-03-21 |
1992-09-23 |
Zeneca Limited |
Alpha, alpha-dialkylbenzyl derivatives
|
US5130485A
(en)
|
1991-04-23 |
1992-07-14 |
Eli Lilly And Company |
N-hydroxy-N-(3-(2-substituted phenyl)prop-2-enyl)ureas and thioureas useful as 5-lipoxygenase inhibiting agents
|
US5283361A
(en)
|
1991-04-23 |
1994-02-01 |
Eli Lilly And Company |
N-hydroxy-N-[3-[2-(halophenylthio)phenyl]prop-2-enyl]ureas as lipoxygenase inhibitors
|
US5147893A
(en)
|
1991-05-09 |
1992-09-15 |
G. D. Searle & Co. |
Cyclic phenolic thioethers
|
US5114958A
(en)
|
1991-05-09 |
1992-05-19 |
Warner-Lambert Company |
1,2,4-oxadiazole and 1,2,4-thiadiazole derivatives of fenamates as antiinflammatory agents
|
US5442111A
(en)
|
1991-05-24 |
1995-08-15 |
Warner-Lambert Company |
3,5-di-tetriary-4-butyl-4-hydroxyphenyloxy- or tioalkylene N-hydroxyamides, N-hydroxythioamides, N-hydroxyureas, and N-hydroxythioureas as 5-lipoxygenase inhibitors
|
SE9101642D0
(sv)
|
1991-05-30 |
1991-05-30 |
Kabi Pharmacia Ab |
Phospholipids
|
US5215630A
(en)
|
1991-06-04 |
1993-06-01 |
Nippon Suisan Kaisha, Ltd. |
Method of purifying eicosapentaenoic acid or the ester derivative thereof by fractional distillation
|
DE4123613C1
(ko)
|
1991-07-17 |
1993-02-04 |
Gruenenthal Gmbh, 5100 Aachen, De |
|
DE4124345A1
(de)
|
1991-07-23 |
1993-01-28 |
Gruenenthal Gmbh |
Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
|
AU2384292A
(en)
|
1991-07-30 |
1993-03-02 |
North Carolina State University |
Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
|
US5250547A
(en)
|
1991-08-29 |
1993-10-05 |
Syntex (U.S.A.) Inc. |
Benzopyran derivatives
|
US5270319A
(en)
|
1991-09-09 |
1993-12-14 |
Warner-Lambert Company |
5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
|
CA2076257A1
(en)
|
1991-09-13 |
1993-03-14 |
Jan Heeres |
4-¬4-¬4-(4-hydroxyphenyl)-1- piperazinyl|phenyl|-5-methyl-3h -1,2,4-triazol-3-one derivatives
|
DE4133694C2
(de)
|
1991-10-11 |
1993-10-07 |
Fresenius Ag |
Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
|
JP3400466B2
(ja)
|
1991-10-28 |
2003-04-28 |
日本水産株式会社 |
高純度エイコサペンタエン酸またはそのエステルの製造方法
|
US5476944A
(en)
|
1991-11-18 |
1995-12-19 |
G. D. Searle & Co. |
Derivatives of cyclic phenolic thioethers
|
AU3128693A
(en)
|
1991-11-18 |
1993-06-15 |
G.D. Searle & Co. |
2-(4-substituted)phenylmethylene derivatives and methods of use
|
US5212189A
(en)
|
1991-12-17 |
1993-05-18 |
Warner-Lambert Company |
Thiadiazole or oxadiazole analogs of fenamic acids containing substituted hydroxamate side chains as antiinflammatory agents
|
US5288896A
(en)
|
1992-01-15 |
1994-02-22 |
Warner-Lambert Company |
3,5-di-t-butyl-4-hydroxylphenylmethylhydroxylamines and their derivatives, pharmaceutical compositions, and methods of use therefor
|
DE4204686A1
(de)
|
1992-02-17 |
1993-08-19 |
Gruenenthal Gmbh |
Imidazolylphenolderivate, diese enthaltende arzneimittel sowie ein verfahren zur herstellung dieser verbindungen und arzneimitteln
|
US5196431A
(en)
|
1992-02-24 |
1993-03-23 |
Warner-Lambert Company |
2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5220025A
(en)
|
1992-02-24 |
1993-06-15 |
Warner-Lambert Company |
2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5530141A
(en)
|
1992-03-04 |
1996-06-25 |
Center For Innovative Technology |
2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5639782A
(en)
|
1992-03-04 |
1997-06-17 |
Center For Innovative Technology |
Neolignan derivatives as platelet activating factor receptor antagonists and 5-lipoxygenase inhibitors
|
US5187175A
(en)
|
1992-03-06 |
1993-02-16 |
Warner-Lambert Company |
2-carbonyl substituted-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
|
US5595872A
(en)
|
1992-03-06 |
1997-01-21 |
Bristol-Myers Squibb Company |
Nucleic acids encoding microsomal trigyceride transfer protein
|
US5215986A
(en)
|
1992-06-01 |
1993-06-01 |
Warner-Lambert Company |
5-hydroxy-2-pyrimidinylmethylene oxaza heterocycles
|
US5208364A
(en)
|
1992-06-25 |
1993-05-04 |
Bristol-Myers Squibb Co. |
Antibiotic 5-lipoxygenase inhibitors
|
US5314898A
(en)
|
1992-06-29 |
1994-05-24 |
Merck & Co., Inc. |
Aryl thiopyrano[4,3,2-cd]indoles as inhibitors of leukotriene biosynthesis
|
US5648486A
(en)
|
1992-07-13 |
1997-07-15 |
Cytomed, Inc. |
Compounds and methods for the treatment of inflammatory and immune disorders
|
US5358938A
(en)
|
1992-07-13 |
1994-10-25 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
PT650485E
(pt)
|
1992-07-13 |
2001-03-30 |
Millennium Pharm Inc |
2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias
|
US5434151A
(en)
|
1992-08-24 |
1995-07-18 |
Cytomed, Inc. |
Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
|
US5463083A
(en)
|
1992-07-13 |
1995-10-31 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5541218A
(en)
|
1992-07-23 |
1996-07-30 |
Pfizer Inc. |
Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors
|
JPH0649479A
(ja)
|
1992-07-28 |
1994-02-22 |
Maruha Corp |
ω−3不飽和脂肪酸系化合物の安定化法
|
US5240929A
(en)
|
1992-08-03 |
1993-08-31 |
Warner-Lambert Company |
2-heterocyclic-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
|
US5888541A
(en)
|
1992-08-21 |
1999-03-30 |
Scotia Holdings Plc |
Fatty acid treatment
|
GB9217780D0
(en)
|
1992-08-21 |
1992-10-07 |
Efamol Holdings |
Fatty acid treatment
|
JPH0692847A
(ja)
|
1992-09-11 |
1994-04-05 |
Mochida Pharmaceut Co Ltd |
骨粗鬆症治療剤
|
WO1994010125A1
(en)
|
1992-10-27 |
1994-05-11 |
Sandoz Ltd. |
Glycerin derivatives and uses thereof
|
US5288751A
(en)
|
1992-11-06 |
1994-02-22 |
Abbott Laboratories |
[(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
|
US5314900A
(en)
|
1992-11-19 |
1994-05-24 |
Merck Frosst Canada, Inc. |
Aryl thiopyrano[2,3,4-C,D]indoles as inhibitors of leukotriene biosynthesis
|
US5292900A
(en)
|
1992-12-18 |
1994-03-08 |
Abbott Laboratories |
O-substituted N-hydroxyurea derivatives
|
US5326907A
(en)
|
1992-12-18 |
1994-07-05 |
G. D. Searle & Co. |
2-aminoethanesulfonic acid derivatives of 3,5-disubstituted-4-hydroxyphenolic thioethers
|
GB9300125D0
(en)
|
1993-01-06 |
1993-03-03 |
Scotia Holdings Plc |
Compositions containing esters of unsaturated fatty acids
|
ES2062943B1
(es)
|
1993-03-23 |
1995-11-16 |
Uriach & Cia Sa J |
Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
|
IL109311A0
(en)
|
1993-04-16 |
1994-07-31 |
Lilly Co Eli |
1H-indole-3-acetamide sPla2 inhibitors
|
AP9400632A0
(en)
|
1993-04-29 |
1995-10-07 |
Zeneca Ltd |
Ether derivatives.
|
WO1994026268A1
(en)
|
1993-05-10 |
1994-11-24 |
Sepracor, Inc. |
Methods and compositions using optically pure (+)-zileuton
|
US6239170B1
(en)
|
1993-05-28 |
2001-05-29 |
Gurpreet S. Ahluwalia |
Inhibition of hair growth
|
AU7053494A
(en)
|
1993-06-04 |
1995-01-03 |
Martek Biosciences Corporation |
Method of treating coronary vascular disease using docosahexaenoic acid
|
JPH0738598A
(ja)
|
1993-06-29 |
1995-02-07 |
Toshiba Corp |
ネットワークアダプタ群管理装置
|
US5739135A
(en)
|
1993-09-03 |
1998-04-14 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
GB9318611D0
(en)
|
1993-09-08 |
1993-10-27 |
Sandoz Nutrition Ltd |
Improvements in or relating to organic compounds
|
US5459154A
(en)
|
1993-11-08 |
1995-10-17 |
American Home Products Corporation |
N-hydroxyureas as 5-lipoxygenase inhibitors and inhibitors of oxidative modification of low density lipoprotein
|
ES2087019B1
(es)
|
1994-02-08 |
1997-03-16 |
Bobel246 S L |
Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
|
JP3325995B2
(ja)
|
1994-02-28 |
2002-09-17 |
ミサワホーム株式会社 |
パネル接合構造
|
GB9403857D0
(en)
|
1994-03-01 |
1994-04-20 |
Scotia Holdings Plc |
Fatty acid derivatives
|
GB9404483D0
(en)
|
1994-03-08 |
1994-04-20 |
Norsk Hydro As |
Refining marine oil compositions
|
AU1326795A
(en)
|
1994-03-09 |
1995-09-25 |
Pfizer Inc. |
Isoxazoline compounds as 5-lipoxygenase inhibitors
|
US6252084B1
(en)
|
1994-03-15 |
2001-06-26 |
Eli Lilly And Company |
1H-indole-3-acetamide sPLA2 inhibitors
|
CA2186513C
(en)
|
1994-03-28 |
1999-03-16 |
James F. Eggler |
Benzisothiazoles derivatives as inhibitors of 5-lipoxygenase biosynthesis
|
UA47387C2
(uk)
|
1994-04-01 |
2002-07-15 |
Елі Ліллі Енд Компані |
1H-ІНДОЛ-3-ГЛІОКСИЛАМІДИ ЯК ІНГІБІТОРИ sPLA<sub>2</sub> ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ
|
US5385929A
(en)
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
US5534524A
(en)
|
1994-05-09 |
1996-07-09 |
Board Of Regents, The University Of Texas System |
Suppression of bone resorption by quinolines
|
US5760081A
(en)
|
1994-05-10 |
1998-06-02 |
The General Hospital Corporation |
Omega 3 fatty acids in the prevention of ventricular fibrillation
|
JP3179286B2
(ja)
|
1994-05-19 |
2001-06-25 |
ファイザー製薬株式会社 |
N−ヒドロキシ尿素系抗炎症剤
|
JP3368100B2
(ja)
|
1994-06-02 |
2003-01-20 |
キヤノン株式会社 |
静電荷像現像用トナー
|
US5792776A
(en)
|
1994-06-27 |
1998-08-11 |
Cytomed, Inc., |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5750565A
(en)
|
1995-05-25 |
1998-05-12 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
US5703093A
(en)
|
1995-05-31 |
1997-12-30 |
Cytomed, Inc. |
Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
|
AU711482B2
(en)
|
1994-06-28 |
1999-10-14 |
Scotia Holdings Plc |
Compositions for treatment of diabetic complications
|
US6214876B1
(en)
|
1994-07-21 |
2001-04-10 |
Eli Lilly And Company |
Indene-1-acetamide sPLA2 inhibitors
|
US5641800A
(en)
|
1994-07-21 |
1997-06-24 |
Eli Lilly And Company |
1H-indole-1-functional sPLA2 inhibitors
|
JPH0850637A
(ja)
|
1994-08-04 |
1996-02-20 |
Toshiba Corp |
帳票類取扱装置
|
IT1274734B
(it)
|
1994-08-25 |
1997-07-24 |
Prospa Bv |
Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
|
US5674488A
(en)
|
1994-10-07 |
1997-10-07 |
Reich; John J. |
Method for prevention and treatment of hyperchlolesterolemia by in vivo hydrogenation of cholesterol
|
US5635514A
(en)
|
1994-10-25 |
1997-06-03 |
G. D. Searle & Company |
Heteroaralkyl and heteroarylthioalkyl thiophenolic compounds as 5-lipoxgenase inhibitors
|
JPH08193074A
(ja)
|
1994-11-18 |
1996-07-30 |
Nippon Bayeragrochem Kk |
除草性1−シクロプロピルテトラゾリノン類
|
JPH08165267A
(ja)
|
1994-12-14 |
1996-06-25 |
Yakult Honsha Co Ltd |
ジアリルヘプタノイド誘導体およびこれを含有する抗炎症剤
|
JP2780154B2
(ja)
|
1995-02-17 |
1998-07-30 |
株式会社ヤクルト本社 |
ヨーグルト
|
US5514703A
(en)
|
1995-03-13 |
1996-05-07 |
Eli Lilly And Company |
Benzothiophene compounds useful for inhibiting lipoxygenase
|
JPH0840981A
(ja)
|
1995-03-24 |
1996-02-13 |
Nissui Pharm Co Ltd |
エイコサペンタエノイルグリセライド
|
US5516789A
(en)
|
1995-04-12 |
1996-05-14 |
Abbott Laboratories |
Lipoxygenase and cyclooxygenase inhibiting compounds
|
MY118354A
(en)
|
1995-05-01 |
2004-10-30 |
Scarista Ltd |
1,3-propane diol derivatives as bioactive compounds
|
GB9509764D0
(en)
|
1995-05-15 |
1995-07-05 |
Tillotts Pharma Ag |
Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
|
WO1996038418A1
(en)
|
1995-06-02 |
1996-12-05 |
G.D. Searle & Co. |
Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
|
CA2224517A1
(en)
|
1995-06-12 |
1996-12-27 |
G.D. Searle & Co. |
Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
|
JPH0959206A
(ja)
|
1995-08-25 |
1997-03-04 |
Nippon Oil & Fats Co Ltd |
エイコサペンタエン酸およびエイコサペンタエン酸エステルの製造方法
|
GB9519661D0
(en)
|
1995-09-27 |
1995-11-29 |
Scotia Holdings Plc |
Fatty acid treatment
|
JP3552810B2
(ja)
|
1995-09-27 |
2004-08-11 |
松下電器産業株式会社 |
部品供給部の部品一括交換方法と装置
|
EP0871713B1
(en)
|
1995-11-09 |
2007-02-14 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis
|
US5763496A
(en)
|
1995-11-27 |
1998-06-09 |
The Research Foundation Of State University Of New York |
Prevention of atherosclerosis using NADPH oxidase inhibitors
|
US5762413A
(en)
|
1996-01-29 |
1998-06-09 |
Alternate Realities Corporation |
Tiltable hemispherical optical projection systems and methods having constant angular separation of projected pixels
|
US6231189B1
(en)
|
1996-01-29 |
2001-05-15 |
Elumens Corporation |
Dual polarization optical projection systems and methods
|
DE69709069T2
(de)
|
1996-02-13 |
2002-07-04 |
G.D. Searle & Co., Chicago |
Zusammensetzungen mit immunosuppressiven wirkungen, welche 5-lipoxygenase-inhibitoren und cyclooxygenase-2-inhibitoren enthalten
|
AU2738497A
(en)
|
1996-04-24 |
1997-11-12 |
Brigham And Women's Hospital |
Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
|
US6077828A
(en)
|
1996-04-25 |
2000-06-20 |
Abbott Laboratories |
Method for the prevention and treatment of cachexia and anorexia
|
AU2927797A
(en)
|
1996-05-06 |
1997-11-26 |
Brigham And Women's Hospital |
5-lipoxygenase gene polymorphisms and their use in classifying patients
|
US6090547A
(en)
|
1997-04-25 |
2000-07-18 |
Brigham & Women's Hospital |
Identification of asthma patients who are candidates for effective treatment with 5-lipoxygenase inhibitors
|
US5827875A
(en)
|
1996-05-10 |
1998-10-27 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US5885983A
(en)
|
1996-05-10 |
1999-03-23 |
Bristol-Myers Squibb Company |
Inhibitors of microsomal triglyceride transfer protein and method
|
US6248398B1
(en)
|
1996-05-22 |
2001-06-19 |
Applied Materials, Inc. |
Coater having a controllable pressurized process chamber for semiconductor processing
|
US6776986B1
(en)
|
1996-06-06 |
2004-08-17 |
Novartis Ag |
Inhibition of HIV-1 replication by antisense RNA expression
|
TW425285B
(en)
|
1996-06-10 |
2001-03-11 |
Viva America Marketing Inc |
Fish oil and garlic nutritive supplement
|
US5998477A
(en)
|
1996-06-13 |
1999-12-07 |
Cell Pathways Inc. |
Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
|
US6063818A
(en)
|
1996-06-13 |
2000-05-16 |
Cell Pathways Inc. |
Substituted benzylidene indenyl formamides, acetamides and propionamides
|
US6121321A
(en)
|
1996-06-13 |
2000-09-19 |
Cell Pathways, Inc. |
Substituted methoxy benzylidene indenyl acetic and propionic acids for treating patients with precancerous lesions
|
US5965619A
(en)
|
1996-06-13 |
1999-10-12 |
Cell Pathways Inc. |
Method for treating patients having precancerous lesions with substituted indene derivatives
|
US5861399A
(en)
|
1996-07-17 |
1999-01-19 |
Heart Care Partners |
Methods and compositions for the rapid and enduring relief of inadequate myocardial function
|
US6005000A
(en)
|
1996-08-22 |
1999-12-21 |
Oxis International, Inc. |
5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
|
DE19636150A1
(de)
|
1996-09-06 |
1998-03-12 |
Asta Medica Ag |
N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
|
US20020055539A1
(en)
|
1996-10-02 |
2002-05-09 |
Bockow Barry I. |
Compositions and methods for treating cardiovascular conditions
|
KR20060061409A
(ko)
|
1996-10-11 |
2006-06-07 |
스카리스타 리미티드 |
에이코사펜타엔산 및/또는 스테아리돈산을 포함하여이루어지는 오일
|
US6426335B1
(en)
|
1997-10-17 |
2002-07-30 |
Gilead Sciences, Inc. |
Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
|
US6569539B2
(en)
|
1996-10-30 |
2003-05-27 |
Tetra Level Holdings & Finance S.A. |
Gas barrier packaging laminate method for production thereof and packaging containers
|
US6177440B1
(en)
|
1996-10-30 |
2001-01-23 |
Eli Lilly And Company |
Substituted tricyclics
|
US6713645B1
(en)
|
1996-10-30 |
2004-03-30 |
Eli Lilly And Company |
Substituted tricyclics
|
JP4176166B2
(ja)
*
|
1996-11-15 |
2008-11-05 |
持田製薬株式会社 |
横紋筋融解症治療剤
|
DK0843972T3
(da)
|
1996-11-20 |
2002-12-02 |
Nutricia Nv |
Næringsmiddelsammensætning, der indeholder fedtstoffer til behandling af stofskiftesygdomme
|
US5909734A
(en)
|
1996-12-03 |
1999-06-08 |
Regents Of The University Of Michigan |
Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
|
US5916922A
(en)
|
1996-12-03 |
1999-06-29 |
Eli Lilly And Company |
Phenyl glyoxamides as SPLA2 inhibitors
|
US6353128B1
(en)
|
1996-12-03 |
2002-03-05 |
Eli Lilly And Company |
Phenyl acetamides as sPLA2 inhibitors
|
ID18983A
(id)
|
1996-12-04 |
1998-05-28 |
Lilly Co Eli |
Pirazola sebagai inhibitor sekresi fosfolipase a2 non-pankreas pada manusia
|
US6011049A
(en)
|
1997-02-19 |
2000-01-04 |
Warner-Lambert Company |
Combinations for diabetes
|
AU6415998A
(en)
|
1997-04-18 |
1998-11-13 |
Pfizer Inc. |
Process and intermediates for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide
|
US6177415B1
(en)
|
1997-04-21 |
2001-01-23 |
The United States Of America As Represented By The Secretary Of Agriculture |
Bacteriohopanetetrol and related compounds useful for modulation of lipoxygenase activity and anti-inflammatory applications
|
JP4231559B2
(ja)
|
1997-04-23 |
2009-03-04 |
オリザ油化株式会社 |
リポキシゲナーゼ阻害剤
|
WO1998047507A1
(en)
|
1997-04-24 |
1998-10-29 |
Shionogi & Co., Ltd. |
Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
|
US20030008816A1
(en)
|
1997-05-28 |
2003-01-09 |
Pilon Aprile L. |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20020169108A1
(en)
|
1997-05-28 |
2002-11-14 |
Pilon Aprile L. |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20060025348A1
(en)
|
1997-05-28 |
2006-02-02 |
Pilon Aprile L |
Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
|
US20010006644A1
(en)
|
1997-07-31 |
2001-07-05 |
David J. Bova |
Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
|
US6767739B2
(en)
|
2001-07-30 |
2004-07-27 |
Isis Pharmaceuticals Inc. |
Antisense modulation of microsomal triglyceride transfer protein expression
|
AU9123198A
(en)
|
1997-08-28 |
1999-03-16 |
Eli Lilly And Company |
Method for treatment of non-rheumatoid athritis
|
IT1304595B1
(it)
|
1997-08-29 |
2001-03-19 |
Giorgio Endrici |
Inibitore della 5-lipoossigenasi
|
JPH1180083A
(ja)
|
1997-09-10 |
1999-03-23 |
Nof Corp |
エイコサペンタエン酸エステルの製造方法
|
US6218524B1
(en)
|
1997-09-16 |
2001-04-17 |
Eurona Medical Ab |
Genetic polymorphisms in the microsomal triglyceride transfer protein promoter and uses thereof
|
US6440961B1
(en)
|
1997-10-27 |
2002-08-27 |
Dr. Reddy's Research Foundation |
Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
|
EP1039911B1
(en)
|
1997-10-27 |
2005-05-25 |
Eli Lilly And Company |
MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS
|
CA2309135A1
(en)
|
1997-10-27 |
1999-05-06 |
Michael Lyle Denney |
N,n-diethylglycolamido ester prodrugs of indole spla2 inhibitors
|
KR100569319B1
(ko)
|
1997-10-30 |
2006-04-07 |
모리시타 진탄 가부시키가이샤 |
불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
|
EP1043991A4
(en)
|
1997-11-14 |
2005-02-02 |
Lilly Co Eli |
TREATMENT OF ALZHEIMER DISEASE
|
AU1405899A
(en)
|
1997-11-14 |
1999-06-07 |
Eli Lilly And Company |
Treatment for alzheimer's disease
|
TR200001522T2
(tr)
|
1997-11-25 |
2000-12-21 |
Warner-Lambert Company |
Lipoprotein oksidasyonunun inhibisyonu.
|
US6121323A
(en)
|
1997-12-03 |
2000-09-19 |
3M Innovative Properties Company |
Bishydroxyureas
|
DE69842121D1
(de)
|
1997-12-10 |
2011-03-17 |
Cyclosporine Therapeutics Ltd |
Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
|
US5948779A
(en)
|
1997-12-12 |
1999-09-07 |
Cell Pathways, Inc. |
Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
US6916841B2
(en)
|
1998-02-25 |
2005-07-12 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
CN1299277A
(zh)
|
1998-03-03 |
2001-06-13 |
盐野义制药株式会社 |
含有磷脂酶抑制剂[[3-(2-氨基-1,2-二氧乙基)-2-乙基-1(苯甲基)-1h-吲哚-4-基]氧基]乙酸钠的药用组合物
|
OA11622A
(en)
|
1998-03-31 |
2004-09-16 |
Inst For Pharm Discovery Inc |
Substituted indolealkanoic acids.
|
JP4412521B2
(ja)
|
1998-03-31 |
2010-02-10 |
塩野義製薬株式会社 |
sPLA2阻害作用を有するピロロ[1,2−a]ピラジン誘導体
|
US6028116A
(en)
|
1998-04-03 |
2000-02-22 |
Cell Pathways, Inc. |
Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
|
US6407261B1
(en)
|
1998-04-17 |
2002-06-18 |
Eli Lilly And Company |
Process for preparing 4-hdyroxy indole, indazole and carbazole compounds
|
DZ2770A1
(fr)
|
1998-04-17 |
2003-12-01 |
Lilly Co Eli |
Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
|
AU3656299A
(en)
|
1998-05-01 |
1999-11-23 |
Eli Lilly And Company |
Spla2 inhibitor compounds for treatment of disease
|
CA2332528A1
(en)
|
1998-05-21 |
1999-11-25 |
Shionogi & Co., Ltd. |
Pyrrolo[1,2-b]pyridazine spla2 inhibitory
|
CA2319495A1
(en)
|
1998-06-08 |
1999-12-16 |
Advanced Medicine, Inc. |
Multibinding inhibitors of microsomal triglyceride transferase protein
|
US20020045271A1
(en)
|
1998-06-10 |
2002-04-18 |
Licata And Tyrrell P.C. |
Compounds and methods for identifying compounds that interact with microsomal triglyceride transfer protein binding sites on apolipoprotein b and modulate lipid biosynthesis
|
AU4710699A
(en)
|
1998-06-30 |
2000-01-17 |
Eli Lilly And Company |
Bicyclic sPLA2 inhibitors
|
DE19830375A1
(de)
|
1998-07-08 |
2000-01-13 |
K D Pharma Bexbach Gmbh |
Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
|
EP1100493A4
(en)
|
1998-08-03 |
2001-10-24 |
Lilly Co Eli |
SPLA 2 INHIBITORS? OF THE INDOLTYPS
|
DE69931496T2
(de)
|
1998-08-03 |
2006-11-23 |
Eli Lilly And Co., Indianapolis |
INDOLVERBINDUNGEN ALS sPLA2 INHIBITOREN
|
US6576654B1
(en)
|
1998-09-23 |
2003-06-10 |
Eli Lilly And Company |
Method for the treatment of cystic fibrosis
|
US6221880B1
(en)
|
1998-10-09 |
2001-04-24 |
Schering Corporation |
Composition and method for treating allergic diseases
|
CA2346334A1
(en)
|
1998-10-14 |
2000-04-20 |
Shionogi & Co., Ltd. |
Composition for treating or preventing ischemia reperfusion injury
|
US20030008914A1
(en)
|
1998-10-16 |
2003-01-09 |
C. Grace Yeh |
Pharmaceutical formulations useful to treat inflammatory and immune disorders
|
US6248553B1
(en)
|
1998-10-22 |
2001-06-19 |
Atairgin Technologies, Inc. |
Enzyme method for detecting lysophospholipids and phospholipids and for detecting and correlating conditions associated with altered levels of lysophospholipids
|
NZ500703A
(en)
|
1998-11-04 |
2001-06-29 |
F |
Preparation of food-grade marine edible oils by treatment with silica, vacuum steam deodorisation and addition of a herb extract
|
TNSN99224A1
(fr)
|
1998-12-01 |
2005-11-10 |
Inst For Pharm Discovery Inc |
Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
|
US20020055529A1
(en)
|
1998-12-02 |
2002-05-09 |
Bisgaier Charles Larry |
Method for treating alzheimer's disease
|
DE69933471T2
(de)
|
1998-12-17 |
2007-08-30 |
Xenogen Corp., Alameda |
Unblutige bestimmung einer physiologischen reaktion in einem säugetier
|
EP1144305A4
(en)
|
1998-12-22 |
2004-11-10 |
Lilly Co Eli |
NEW sPLA 2 INHIBITORS
|
ATE247119T1
(de)
|
1998-12-22 |
2003-08-15 |
Lilly Co Eli |
Substituierte pyrroloindole
|
US6194585B1
(en)
|
1998-12-22 |
2001-02-27 |
Pfizer Inc. |
Process for preparing 5-lipoxygenase inhibitors
|
EP1140187B1
(en)
|
1998-12-23 |
2003-09-03 |
G.D. Searle LLC. |
Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
CA2260397A1
(en)
|
1999-01-29 |
2000-07-29 |
Atlantis Marine Inc. |
Method of converting rendered triglyceride oil from marine sources into bland, stable food oil
|
US20030104048A1
(en)
|
1999-02-26 |
2003-06-05 |
Lipocine, Inc. |
Pharmaceutical dosage forms for highly hydrophilic materials
|
US6193999B1
(en)
|
1999-03-01 |
2001-02-27 |
Banner Pharmacaps, Inc. |
Gum acacia substituted soft gelatin capsules
|
DE60005152T2
(de)
|
1999-03-03 |
2004-07-08 |
Eurovita A/S |
Arzneimittel, nahrungszusätze und kosmetische zubereitung enthaltend eine fettsäure und ingwer
|
DK1166652T4
(en)
|
1999-03-04 |
2016-10-24 |
Suntory Holdings Ltd |
The use of material containing 4, 7, 10, 13, 16-docosapentaenoic acid
|
US20020110523A1
(en)
|
1999-03-23 |
2002-08-15 |
Cornelis Kluft |
Methods for screening or monitoring the risk of cardiovascular disease relating to sex steroid compound or composition intake and methods for screening sex steroid compound
|
US20020054871A1
(en)
|
1999-04-12 |
2002-05-09 |
Yadong Huang |
Methods and compositions for use in the treatment of hyperlipidemia
|
US6380397B1
(en)
|
1999-04-15 |
2002-04-30 |
Eli Lilly And Company |
Process for preparing 4-substituted-1H-indole-3-glyoxamides
|
US6274578B1
(en)
|
1999-04-20 |
2001-08-14 |
Eli Lilly And Company |
sPLA2 inhibitor ester
|
JP2001025519A
(ja)
|
1999-05-11 |
2001-01-30 |
Mamiya Op Co Ltd |
ゴルフクラブ用シャフト
|
US6140327A
(en)
|
1999-05-12 |
2000-10-31 |
Eli Lilly And Company |
Morpholino-n-ethyl ester derivative of an indole sPLA2 inhibitor
|
US7112609B2
(en)
|
1999-06-01 |
2006-09-26 |
Drugtech Corporation |
Nutritional supplements
|
US6207699B1
(en)
|
1999-06-18 |
2001-03-27 |
Richard Brian Rothman |
Pharmaceutical combinations for treating obesity and food craving
|
CA2311974A1
(en)
|
1999-06-28 |
2000-12-28 |
Nisshin Flour Milling Co., Ltd. |
Processes of selectively separating and purifying eicosapentaenoic and docosahexaenoic acids or their esters
|
GB9916536D0
(en)
*
|
1999-07-14 |
1999-09-15 |
Scarista Limited |
Nutritional or pharmaceutical compositions
|
US6706752B1
(en)
|
1999-07-19 |
2004-03-16 |
Eli Lilly And Company |
sPLA2 inhibitors
|
JP4636521B2
(ja)
|
1999-07-19 |
2011-02-23 |
塩野義製薬株式会社 |
sPLA2阻害作用を有する三環系化合物
|
DE19933926A1
(de)
|
1999-07-20 |
2001-01-25 |
Boehringer Ingelheim Pharma |
Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
|
ATE394941T1
(de)
|
1999-07-28 |
2008-05-15 |
Swiss Caps Rechte & Lizenzen |
Präparat zur verwendung als medikament und/oder nahrungsmittelergänzung
|
JP4636522B2
(ja)
|
1999-08-02 |
2011-02-23 |
塩野義製薬株式会社 |
sPLA2阻害作用を有する三環式化合物
|
AU6762400A
(en)
|
1999-08-12 |
2001-03-13 |
Cor Therapeutics, Inc. |
Inhibitors of factor xa
|
US6787545B1
(en)
|
1999-08-23 |
2004-09-07 |
Shiongi & Co., Ltd. |
Pyrrolotriazine derivatives having spla2-inhibitory activities
|
WO2001015552A1
(en)
|
1999-08-30 |
2001-03-08 |
Ocean Nutrition Canada Ltd. |
A nutritional supplement for lowering serum triglyceride and cholesterol levels
|
US6344563B1
(en)
|
1999-08-31 |
2002-02-05 |
Timothy Norris |
Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems
|
US6831095B1
(en)
|
1999-09-20 |
2004-12-14 |
Eli Lilly And Company |
Hydroxyfunctional amide 1h-indole derivatives active as sPLA2 inhibitors
|
CA2385406A1
(en)
|
1999-09-21 |
2001-03-29 |
Shionogi & Co., Ltd. |
Gene encoding novel human secretory phospholipase a2
|
US6608227B1
(en)
|
1999-10-15 |
2003-08-19 |
Bristol-Myers Squibb Pharma |
Benzylcycloalkyl amines as modulators of chemokine receptor activity
|
US6261607B1
(en)
|
1999-10-19 |
2001-07-17 |
Thomas Newmark |
Composition for promoting prostate health containing selenium and herbal extracts
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
CA2325358C
(en)
|
1999-11-10 |
2005-08-02 |
Pfizer Products Inc. |
7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
|
AU1304801A
(en)
|
1999-11-15 |
2001-05-30 |
Shionogi & Co., Ltd. |
Tricyclic azaindolizine derivatives having an SPLA2- inhibiting effect
|
JP4170542B2
(ja)
|
1999-11-18 |
2008-10-22 |
日油株式会社 |
高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
|
DE19962300A1
(de)
|
1999-12-23 |
2001-06-28 |
Asta Medica Ag |
Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
|
DE60110896T2
(de)
|
2000-01-18 |
2006-01-12 |
Novartis Ag |
Carboxamide und ihre verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und der apolipoprotein b (apo b) sekretion
|
EP1125914A1
(en)
|
2000-02-14 |
2001-08-22 |
Nisshin Flour Milling Co., Ltd. |
Process for separating and purifying eicosapentaenoic acid or its ester
|
DE10007203A1
(de)
|
2000-02-17 |
2001-08-23 |
Asta Medica Ag |
Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
|
SE0000754D0
(sv)
|
2000-03-07 |
2000-03-07 |
Amersham Pharm Biotech Ab |
Mass spectral peak identification
|
RU2281764C2
(ru)
|
2000-03-17 |
2006-08-20 |
Адзиномото Ко., Инк. |
Лекарственные средства для лечения осложнений, связанных с диабетом, и невропатии и их применения
|
US7387797B2
(en)
|
2000-03-22 |
2008-06-17 |
Creighton University |
Compositions derived from Modiolus modiolus and methods for making and using same
|
WO2001079560A2
(en)
|
2000-04-17 |
2001-10-25 |
Glaxo Group Limited |
Medicine response assay in respiratory disease
|
US6987105B2
(en)
|
2000-04-28 |
2006-01-17 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of thienotriazolodiazepines
|
DE10022925A1
(de)
|
2000-05-11 |
2001-11-15 |
Basf Ag |
Substituierte Indole als PARP-Inhibitoren
|
DK1157692T3
(da)
|
2000-05-22 |
2006-02-06 |
Pro Aparts Investimentos E Con |
Sammensætning af fedtsyrer indeholdende mindst 80 vægt-% EPA og DHA, derivater deraf og farmaceutisk anvendelse deraf
|
GB0013378D0
(en)
|
2000-06-01 |
2000-07-26 |
Glaxo Group Ltd |
Use of therapeutic benzamide derivatives
|
US6620821B2
(en)
|
2000-06-15 |
2003-09-16 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
DE10030375A1
(de)
|
2000-06-21 |
2002-01-03 |
Bayer Ag |
Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
|
JP2004501910A
(ja)
|
2000-06-28 |
2004-01-22 |
イーライ・リリー・アンド・カンパニー |
新規なsPLA2インヒビター
|
AU2001267823A1
(en)
|
2000-06-29 |
2002-01-08 |
Shionogi And Co., Ltd. |
Compounds exhibiting x-type spla2 inhibiting effect
|
WO2002000257A1
(fr)
|
2000-06-29 |
2002-01-03 |
Shionogi & Co., Ltd. |
Remedes a la maladie d'alzheimer
|
TW583000B
(en)
|
2000-06-29 |
2004-04-11 |
Shionogi & Co |
X-type sPLA2 inhibitor as a cancer therapeutical agent
|
GB0016045D0
(en)
|
2000-06-29 |
2000-08-23 |
Laxdale Limited |
Therapeutic combinations of fatty acids
|
WO2002000256A1
(en)
|
2000-06-29 |
2002-01-03 |
Shionogi & Co., Ltd. |
Remedies for cirrhosis
|
GB0016452D0
(en)
|
2000-07-04 |
2000-08-23 |
Kilgowan Limited |
Vitamin K and essential fatty acids
|
US20020032238A1
(en)
|
2000-07-08 |
2002-03-14 |
Henning Priepke |
Biphenylcarboxylic acid amides, the preparation thereof and the use thereof as medicaments
|
US7253194B2
(en)
|
2000-07-24 |
2007-08-07 |
The University Of Queensland |
Compounds and inhibitors of phospholipases
|
WO2002011723A1
(en)
|
2000-08-04 |
2002-02-14 |
Mason R Preston |
Synergistic effect of amlodipine and atorvastatin
|
JP4391673B2
(ja)
|
2000-08-08 |
2009-12-24 |
花王株式会社 |
油脂組成物
|
US6417367B1
(en)
|
2000-08-11 |
2002-07-09 |
Pfizer Inc. |
Methods of making quinoline amides
|
DZ3409A1
(fr)
|
2000-08-15 |
2002-02-21 |
Pfizer Prod Inc |
Association therapeuthique
|
AU2001284876A1
(en)
|
2000-08-15 |
2002-02-25 |
South Alabama Medical Science Foundation |
Treating sickle cell disease
|
US6383482B1
(en)
|
2000-08-24 |
2002-05-07 |
Vitacost.Com, Inc. |
Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
|
US20120237626A9
(en)
|
2000-12-05 |
2012-09-20 |
Palu Afa Kehaati |
Profiles of lipid proteins and inhibiting HMG-CoA reductase
|
CA2430808A1
(en)
|
2000-12-18 |
2002-06-27 |
Eli Lilly And Company |
Cycloalkylfused [g]-indole compounds as spla2-inhibitors in the treatment of inflammatory diseases
|
JP2004518657A
(ja)
|
2000-12-18 |
2004-06-24 |
イーライ・リリー・アンド・カンパニー |
新規なsPLA2インヒビター
|
DE60126831D1
(de)
|
2000-12-18 |
2007-04-05 |
Lilly Co Eli |
Benz(g)indole und deren verwendung als spla2 inhibitoren
|
WO2002050034A2
(en)
|
2000-12-18 |
2002-06-27 |
Eli Lilly And Company |
Tetracyclic carbazole derivates and their use as spla2 inhibitors
|
GB0101198D0
(en)
|
2001-01-17 |
2001-02-28 |
Scherer Technologies Inc R P |
Ingestible compositions containing an odoriferous oil
|
EP1354208A2
(en)
|
2001-01-19 |
2003-10-22 |
Cambridge Scientific, Inc. |
Methods of diagnosis and treatment of osteoporosis
|
ITMI20010129A1
(it)
|
2001-01-25 |
2002-07-25 |
Pharmacia & Upjohn Spa |
Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
|
AU2002240286A1
(en)
|
2001-02-08 |
2002-08-19 |
Millennium Pharmaceuticals, Inc. |
Detection of polymorphisms in the human 5-lipoxygenase gene
|
TWI314457B
(ko)
|
2001-03-19 |
2009-09-11 |
Shionogi & Co |
|
DE60218155D1
(de)
|
2001-03-28 |
2007-03-29 |
Lilly Co Eli |
Substituierte carbazole als inhibitoren von spla2
|
US7524635B2
(en)
|
2003-04-17 |
2009-04-28 |
Biosite Incorporated |
Methods and compositions for measuring natriuretic peptides and uses thereof
|
GB0111282D0
(en)
|
2001-05-09 |
2001-06-27 |
Laxdale Ltd |
Potentiation of therapeutic effects of fatty acids
|
IL143379A
(en)
|
2001-05-24 |
2013-11-28 |
Yissum Res Dev Co |
Oligonucleotide against human ache isoform r and its uses
|
PT1390025E
(pt)
|
2001-05-30 |
2005-08-31 |
Laxdale Ltd |
Utilizacao de coenzima q (ubiquinona) e acido eicosapentaenoico (epa) para o tratamento de linfoma nao de hodgkin e de distubios psiquiatricos ou neurologicos
|
US7901713B2
(en)
|
2001-06-20 |
2011-03-08 |
Metaproteomics, Llc |
Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
|
US6756399B2
(en)
|
2001-06-29 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
|
US6730694B1
(en)
|
2001-07-20 |
2004-05-04 |
Eli Lilly And Company |
sPLA2 inhibitors
|
US20120214771A1
(en)
|
2001-07-27 |
2012-08-23 |
Fontini Sampalis |
Compositions for treatment of cardiometabolic disorders
|
JP2005527464A
(ja)
|
2001-08-09 |
2005-09-15 |
イーライ・リリー・アンド・カンパニー |
sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
|
DE60208065T2
(de)
|
2001-08-09 |
2006-07-13 |
Eli Lilly And Co., Indianapolis |
Cyclohept'b! indolderivate als spla2-inhibitoren
|
JP2005504795A
(ja)
|
2001-09-13 |
2005-02-17 |
シンタ ファーマスーティカルズ コーポレイション |
癌処置のための1−グリオキシリルアミドインドリジン類
|
JP2005504790A
(ja)
|
2001-09-13 |
2005-02-17 |
シンタ ファーマスーティカルズ コーポレイション |
癌を治療するための3−グリオキシリルアミドインドール
|
ITMI20012384A1
(it)
|
2001-11-12 |
2003-05-12 |
Quatex Nv |
Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
|
US20030144219A1
(en)
|
2001-11-15 |
2003-07-31 |
Phinney Stephen Dodge |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
US20040018248A1
(en)
|
2001-11-29 |
2004-01-29 |
Adrianne Bendich |
Composition containing statins and calcium for improved cardiovascular health
|
AU2002364900A1
(en)
|
2001-11-30 |
2003-06-17 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
|
US7101875B2
(en)
|
2001-12-03 |
2006-09-05 |
Wyeth |
Methods for treating arthritic disorders
|
US6797708B2
(en)
|
2001-12-03 |
2004-09-28 |
Wyeth |
Inhibitors of cytosolic phospholipase A2
|
US6635771B2
(en)
|
2001-12-03 |
2003-10-21 |
Wyeth |
N-benzhydryl indole compounds
|
US6984735B2
(en)
|
2001-12-03 |
2006-01-10 |
Wyeth |
Process for making an aldehyde
|
TWI323658B
(en)
|
2001-12-06 |
2010-04-21 |
Nat Health Research Institutes |
Novel compounds of indol-3-yl-2-oxyacetylamide derivatives, pharmaceutical composition thereof, and method for manufacturing the same
|
US6992100B2
(en)
|
2001-12-06 |
2006-01-31 |
Eli Lilly And Company |
sPLA2 inhibitors
|
ITMI20020269A1
(it)
|
2002-02-12 |
2003-08-12 |
Victorix Assets Ltd |
Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
|
JP2003306690A
(ja)
|
2002-02-18 |
2003-10-31 |
Nooburu:Kk |
多価不飽和脂肪酸含有油脂組成物
|
HUP0200686A2
(hu)
|
2002-02-22 |
2003-09-29 |
EURO- "H" Beruházásszervezż és Ingatlanhasznosító Kft. |
Elektronikus berendezés és eljárás számsorozat eltalálására irányuló játékokban való részvételre kommunikációs berendezésen keresztül
|
US20030166614A1
(en)
|
2002-03-01 |
2003-09-04 |
Harrison Stanley F. |
Method for reducing cholesterol and triglycerides
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
ES2330097T3
(es)
|
2002-04-30 |
2009-12-04 |
Unigen Pharmaceuticals, Inc. |
Formulacion de una mezcla de flavanos y flavonoides de anillo b libre como un agente terapeutico.
|
CA2485116C
(en)
|
2002-05-03 |
2013-02-05 |
Pronova Biocare As |
Use of epa and dha in secondary prevention
|
EP1549299B1
(en)
|
2002-06-05 |
2014-08-20 |
IVAX Pharmaceuticals s.r.o. |
Reduction of gelatin cross-linking
|
US20030092767A1
(en)
|
2002-06-07 |
2003-05-15 |
Macias William Louis |
Combination therapy for the treatment of inflammatory and respiratory diseases
|
US7157235B2
(en)
|
2002-06-17 |
2007-01-02 |
St. Vincent's Hospital Sydney Limited |
Methods of diagnosis, prognosis and treatment of cardiovascular disease
|
US20040077691A1
(en)
|
2002-06-21 |
2004-04-22 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US6620813B1
(en)
|
2002-06-21 |
2003-09-16 |
Medinox, Inc. |
Hydroxamate derivatives of non-steroidal anti-inflammatory drugs
|
US20040001874A1
(en)
|
2002-06-24 |
2004-01-01 |
Vital Living, Inc. |
Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
|
US6653311B1
(en)
|
2002-06-25 |
2003-11-25 |
Board Of Supervisors Of Louisiana State University |
5-lipoxygenase inhibitors: (2-azinylamino) quinone derivatives
|
CA2491445A1
(en)
|
2002-07-02 |
2004-01-15 |
Galileo Pharmaceuticals, Inc. |
Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
|
US20060211761A1
(en)
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
US20080200453A1
(en)
|
2002-07-29 |
2008-08-21 |
Cincotta Anthony H |
Methods of treating metabolic syndrome using dopamine receptor agonists
|
US20030087944A1
(en)
|
2002-08-05 |
2003-05-08 |
Macias William Louis |
Method for the treatment of renal dysfunction with spla2 inhibitors
|
US7314643B2
(en)
|
2002-08-20 |
2008-01-01 |
Nikken Chemicals Co., Ltd. |
Soft capsule preparation
|
DE20214847U1
(de)
|
2002-09-24 |
2004-02-19 |
Voss Automotive Gmbh |
Anschlußvorrichtung für Rohrleitungen
|
KR100539027B1
(ko)
|
2002-10-18 |
2005-12-26 |
현대모비스 주식회사 |
차량의 조향각 검출 장치
|
US7511131B2
(en)
|
2002-11-13 |
2009-03-31 |
Genzyme Corporation |
Antisense modulation of apolipoprotein B expression
|
US8106019B2
(en)
|
2002-11-15 |
2012-01-31 |
Philadelphia Health & Education Corporation |
CHEC-7 a novel sPLA2 inhibitor
|
US7528112B2
(en)
|
2002-11-15 |
2009-05-05 |
Drexel University |
Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
|
TW200418957A
(en)
|
2002-11-22 |
2004-10-01 |
Nippon Suisan Kaiaha Ltd |
Compositions for external use containing polyunsaturated fatty acids salts thereof or esters thereof and method of manufacturing the same
|
US8017651B2
(en)
*
|
2002-11-22 |
2011-09-13 |
Bionexus, Ltd. |
Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
|
ITMI20022511A1
(it)
*
|
2002-11-26 |
2004-05-27 |
Victorix Assets Ltd |
Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
|
GB0228079D0
(en)
|
2002-12-02 |
2003-01-08 |
Laxdale Ltd |
Huntington's Disease
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
US20040198800A1
(en)
|
2002-12-19 |
2004-10-07 |
Geoffrey Allan |
Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
|
EP1578725A1
(en)
|
2002-12-20 |
2005-09-28 |
Pfizer Products Inc. |
Microsomal triglyceride transfer protein inhibitors
|
WO2004056775A1
(en)
|
2002-12-20 |
2004-07-08 |
Pfizer Products Inc. |
Microsomal triglyceride transfer protein inhibitors
|
US20050215625A9
(en)
|
2003-01-08 |
2005-09-29 |
Nesselroad James M Iii |
Combination therapy for anticoagulation
|
NZ541232A
(en)
|
2003-01-09 |
2008-02-29 |
Astellas Pharma Inc |
Pyrrolopyridazine derivatives
|
GB0301701D0
(en)
|
2003-01-24 |
2003-02-26 |
Ensay Ltd |
Psoriasis and Eicosapentaenoic acid
|
CN1816287A
(zh)
|
2003-01-31 |
2006-08-09 |
宝洁公司 |
改善哺乳动物角质组织外观的方法
|
WO2004069238A1
(ja)
|
2003-02-07 |
2004-08-19 |
Mochida Pharmaceutical Co., Ltd. |
くも膜下出血の予後改善剤
|
EP1596854A4
(en)
|
2003-02-14 |
2007-06-06 |
Childrens Hosp & Res Ct Oak |
TREATMENT OF DISEASES RELATED TO REDUCED STICK OXIDE BIOVERABILITY, INCLUDING INCREASED ARGINASE
|
US20060088502A1
(en)
|
2003-02-21 |
2006-04-27 |
Michio Sata |
Drug for reducing side effects in ribavirin interferon combination therapy
|
CN1756545A
(zh)
|
2003-03-05 |
2006-04-05 |
索尔瓦药物有限公司 |
ω-3-脂肪酸在治疗糖尿病患者中的应用
|
EP1605781A1
(en)
*
|
2003-03-18 |
2005-12-21 |
Novartis AG |
Compositions comprising fatty acids and amino acids
|
US20050090426A1
(en)
|
2003-03-24 |
2005-04-28 |
Blumberg Richard S. |
Methods of inhibiting inflammation
|
US20050234073A1
(en)
|
2003-03-24 |
2005-10-20 |
Blumberg Richard S |
Methods of inhibiting inflammation
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
US7329682B2
(en)
|
2003-04-03 |
2008-02-12 |
Ewha University-Industry Collaboration Foundation |
Method for inhibiting 5-lipoxygenase using a benzoxazole derivative
|
US20070066577A1
(en)
|
2003-04-03 |
2007-03-22 |
Hea Young Park Choo |
Benzoxazole derivative or analogue thereof for inhibiting 5-lipoxygenase and pharmaceutical composition containing same
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7579433B2
(en)
|
2003-04-30 |
2009-08-25 |
National University Of Singapore |
Methods and compositions for treatment of arthritis and cancer
|
US7176281B2
(en)
|
2003-04-30 |
2007-02-13 |
National University Of Singapore |
Phospholipase A2-inhibitory peptide with anti-arthritic and neuroprotective activities
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
US6846942B2
(en)
|
2003-05-20 |
2005-01-25 |
David Rubin |
Method for preparing pure EPA and pure DHA
|
US20040235807A1
(en)
|
2003-05-21 |
2004-11-25 |
Weinrich Karl P. |
Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
|
US7205329B2
(en)
|
2003-05-30 |
2007-04-17 |
Microbia, Inc. |
Modulators of CRTH2 activity
|
US20070098787A1
(en)
|
2003-06-20 |
2007-05-03 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing and treating varicose veins of lower extremities
|
US20050042214A1
(en)
|
2003-07-15 |
2005-02-24 |
Gershwin M. Eric |
Discovery of the microorganism that causes the human autoimmune disease, primary biliary cirrhosis
|
RU2356889C2
(ru)
|
2003-07-17 |
2009-05-27 |
Плекссикон, Инк. |
Соединения, являющиеся активными по отношению к рецепторам, активируемым пролифератором пероксисом
|
ATE457166T1
(de)
|
2003-07-24 |
2010-02-15 |
Wockhardt Ltd |
Orale zusammensetzungen zur behandlung von diabetes
|
DE602004008474T2
(de)
|
2003-07-31 |
2008-05-15 |
Wyeth |
N-sulfonylheterocyclopyrrolylalkylamin-verbindungen als 5-hydroxytryptamin-6-liganden.
|
WO2005013907A2
(en)
|
2003-08-07 |
2005-02-17 |
Japan Tobacco Inc. |
Pyrrolo[1,2-b]pyridazine derivatives
|
WO2005018436A2
(en)
|
2003-08-26 |
2005-03-03 |
The Trustees Of Boston University |
Methods for the diagnosis, prognosis and treatment of metabolic syndrome
|
WO2005028653A1
(en)
|
2003-09-22 |
2005-03-31 |
Biospecific Gmbh & Co. Kg |
Method for neutralizing effects of secreted pla2 iia
|
IL158600A
(en)
|
2003-10-26 |
2015-07-30 |
Hermona Soreq |
Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
|
AU2004290051A1
(en)
|
2003-11-12 |
2005-05-26 |
E.I. Dupont De Nemours And Company |
Delta-15 desaturases suitable for altering levels of polyunsaturated fatty acids in oilseed plants and oleaginous yeast
|
ITMI20032247A1
(it)
|
2003-11-19 |
2005-05-20 |
Tiberio Bruzzese |
Interazione di derivati polari di composti insaturi con substrati inorganici
|
SE0303513D0
(sv)
|
2003-12-19 |
2003-12-19 |
Pronova Biocare As |
Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof
|
GB2409644B
(en)
|
2003-12-31 |
2005-12-21 |
Igennus Ltd |
Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
|
IL159729A0
(en)
|
2004-01-06 |
2004-06-20 |
Doron I Friedman |
Non-aqueous composition for oral delivery of insoluble bioactive agents
|
GB0403247D0
(en)
|
2004-02-13 |
2004-03-17 |
Tillotts Pharma Ag |
A pharmaceutical composition
|
US7022713B2
(en)
|
2004-02-19 |
2006-04-04 |
Kowa Co., Ltd. |
Hyperlipemia therapeutic agent
|
EP1591114A1
(en)
|
2004-03-12 |
2005-11-02 |
Fournier Laboratories Ireland Limited |
Use of metformin and orlistat for the treatment or prevention of obesity
|
US20050215640A1
(en)
|
2004-03-26 |
2005-09-29 |
Baxter Jeffrey H |
HMB compositions and uses thereof
|
US7923043B2
(en)
|
2004-03-30 |
2011-04-12 |
Theta Biomedical Consulting & Development Co., Inc. |
Method for protecting humans against superficial vasodilator flush syndrome
|
US20050244367A1
(en)
|
2004-05-03 |
2005-11-03 |
Ilypsa, Inc. |
Phospholipase inhibitors localized in the gastrointestinal lumen
|
US20050272095A1
(en)
|
2004-05-19 |
2005-12-08 |
Ppd Biomarker Discovery Sciences, Llc |
Methods of identifying biomarkers
|
US20050267145A1
(en)
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
TW200613009A
(en)
|
2004-06-11 |
2006-05-01 |
Ono Pharmaceutical Co |
Capsule having chewing stability
|
GB0413730D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
GB0413729D0
(en)
|
2004-06-18 |
2004-07-21 |
Tillotts Pharma Ag |
A pharmaceutical composition and its use
|
CA2573779A1
(en)
|
2004-07-16 |
2006-01-26 |
I.N.S.E.R.M. (Institut National De La Sante Et De La Recherche Medicale) |
Cardiovascular prognostic and diagnostic marker
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
MX2007001155A
(es)
|
2004-07-29 |
2007-08-14 |
Creabilis Therapeutics Spa |
Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
|
US20070231345A1
(en)
|
2004-08-02 |
2007-10-04 |
Muhammed Majeed |
Medicament containing natural leucotriene inhibitors singly or in combination with bioavailable organic selenium supplement for hyperproliferative dermatological conditions and therapeutic methods thereof
|
ITRM20040395A1
(it)
*
|
2004-08-03 |
2004-11-03 |
Sigma Tau Ind Farmaceuti |
Composizione comprendente statine e acidi grassi omega 3.
|
WO2007130713A1
(en)
|
2006-02-01 |
2007-11-15 |
Transform Pharmaceuticals, Inc. |
Novel fenofibrate formulations and related methods of treatment
|
US20090042979A1
(en)
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
WO2006017627A2
(en)
|
2004-08-06 |
2006-02-16 |
Barry Sears |
Dietary compositions comprising docosahexaenoic acid and eicosapentaenoic acid and use thereof for treating insulin resistance
|
RU2382642C2
(ru)
*
|
2004-08-06 |
2010-02-27 |
Трансформ Фармасьютикалз, Инк. |
Новые фармацевтические композиции статина и связанные с ними способы лечения
|
EP1786414A4
(en)
|
2004-08-06 |
2008-04-09 |
Transform Pharmaceuticals Inc |
NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
|
WO2007130714A1
(en)
|
2006-02-01 |
2007-11-15 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
EP1782807B1
(en)
|
2004-08-18 |
2017-08-09 |
Mochida Pharmaceutical Co., Ltd. |
Jelly composition
|
AU2005280058B2
(en)
|
2004-08-25 |
2010-09-02 |
Essentialis, Inc. |
Pharmaceutical formulations of potassium ATP channel openers and uses thereof
|
EP1782801A4
(en)
|
2004-08-27 |
2008-08-06 |
Senju Pharma Co |
EYEWASH FLUID FOR THERAPY DRY EYES
|
KR100545304B1
(ko)
|
2004-09-01 |
2006-05-08 |
주식회사 유니젠 |
아선약을 포함하는 운카리아 속 식물, 또는 이의 황금및/또는 녹차의 배합물을 포함하는 사이클로옥시게나제및/또는 5-리폭시게나제 억제용 조성물
|
WO2006027776A1
(en)
|
2004-09-07 |
2006-03-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
CA2581816A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Sigmoid Biotechnologies Limited |
Microcapsules comprising a methylxanthine and a corticosteroid
|
WO2006044556A2
(en)
|
2004-10-14 |
2006-04-27 |
Galileo Pharmaceuticals, Inc. |
Dual inhibitors of lipoxygenase for treating diabetes
|
JP5491697B2
(ja)
|
2004-10-15 |
2014-05-14 |
フォトンズ コーポレイション リミテッド |
高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物
|
ES2255426B1
(es)
*
|
2004-10-19 |
2007-08-16 |
Gp Pharm, S.A. |
Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
|
KR101086037B1
(ko)
|
2004-10-27 |
2011-11-22 |
에스케이케미칼주식회사 |
호흡기질환 예방 및 치료에 유용한 산두근 추출물
|
CA2588953A1
(en)
|
2004-11-30 |
2006-06-08 |
Plexxikon, Inc. |
Ppar active compounds
|
FR2878747B1
(fr)
|
2004-12-03 |
2007-03-30 |
Pierre Fabre Medicament Sa |
Utilisation d'acide(s) gras omega-3 pour le traitement de l'hypercholesterolemie causee par un traitement anti-retroviral chez les patients infectes par le vih
|
US20090239927A1
(en)
|
2004-12-06 |
2009-09-24 |
George Bobotas |
Statin and Omega-3 Fatty Acids For Lipid Therapy
|
CA2589654C
(en)
|
2004-12-06 |
2016-02-16 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids and dyslipidemic agent for lipid therapy
|
CN101098690A
(zh)
|
2004-12-06 |
2008-01-02 |
瑞莱恩特医药品有限公司 |
用于血脂治疗的ω-3脂肪酸和脂血异常剂
|
US20070191467A1
(en)
|
2004-12-06 |
2007-08-16 |
Reliant Pharmaceutical, Inc. |
Statin and omega-3 fatty acids for lipid therapy
|
US20060135610A1
(en)
|
2004-12-22 |
2006-06-22 |
Bortz Jonathan D |
Cardiovascular compositions
|
GB2421909A
(en)
|
2004-12-23 |
2006-07-12 |
Laxdale Ltd |
Pharmaceutical compositions comprising EPA and methods of use
|
WO2006073147A1
(ja)
|
2005-01-04 |
2006-07-13 |
Mochida Pharmaceutical Co., Ltd. |
脂肪毒性の改善剤
|
US20080200707A1
(en)
|
2005-01-04 |
2008-08-21 |
Mochida-Pharmaceuticals Pharmaceutical Co., Ltd. |
Lipotoxicity Relieving Agent
|
ATE528005T1
(de)
|
2005-01-10 |
2011-10-15 |
Cortendo Ab Publ |
2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
|
US20060172012A1
(en)
|
2005-01-28 |
2006-08-03 |
Finley John W |
Anti-inflammatory supplement compositions and regimens to reduce cardiovascular disease risks
|
US20060189682A1
(en)
|
2005-02-02 |
2006-08-24 |
Payne Joseph E |
Water soluble prodrugs of COX-2 inhibitors
|
WO2006086498A2
(en)
|
2005-02-08 |
2006-08-17 |
Aspreva Pharmaceuticals Sa |
Treatment of vascular, autoimmune and inflammatory diseases using low dosages of impdh inhibitors
|
CN101189011A
(zh)
|
2005-02-17 |
2008-05-28 |
默克公司 |
治疗动脉粥样硬化、脂质异常和相关状况的方法
|
US20100254951A1
(en)
|
2005-02-22 |
2010-10-07 |
Mochida Pharmaceutical Co., Ltd. |
Nerve Regeneration Promoting Agent
|
BRPI0607569A2
(pt)
|
2005-03-08 |
2009-09-15 |
Reliant Pharmaceuticals Inc |
composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
|
BRPI0607555A2
(pt)
|
2005-04-19 |
2009-09-15 |
Surface Logix Inc |
inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
|
AU2006242914B2
(en)
|
2005-05-04 |
2012-02-02 |
Pronova Biopharma Norge As |
New DHA derivatives and their use as medicaments
|
JP2008542255A
(ja)
|
2005-05-27 |
2008-11-27 |
ファイザー・プロダクツ・インク |
肥満症の治療または体重減量の維持のためのカンナビノイド−1受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
|
JP2008542355A
(ja)
|
2005-05-31 |
2008-11-27 |
ファイザー株式会社 |
Vr1アンタゴニストとしての置換アリールオキシ−n−ビシクロメチルアセトアミド化合物
|
CA2570763C
(en)
*
|
2005-07-08 |
2011-08-23 |
Mochida Pharmaceutical Co., Ltd. |
Composition for preventing onset of cardiovascular events
|
JP5134916B2
(ja)
|
2005-07-08 |
2013-01-30 |
持田製薬株式会社 |
心血管イベント発症予防用組成物
|
CN101495106A
(zh)
|
2005-07-18 |
2009-07-29 |
瑞莱恩特医药品有限公司 |
用基于氮杂环丁酮的胆固醇吸收抑制剂和ω-3脂肪酸进行的治疗及其组合产品
|
US7628027B2
(en)
|
2005-07-19 |
2009-12-08 |
Hussmann Corporation |
Refrigeration system with mechanical subcooling
|
WO2007010499A2
(en)
|
2005-07-22 |
2007-01-25 |
Ranbaxy Laboratories Limited |
Derivatives of monosaccharides for the treatment of copd and allergic rhinitis
|
RU2290185C1
(ru)
|
2005-07-26 |
2006-12-27 |
Дмитрий Николаевич Мясников |
Композиция для нормализации липидного обмена и снижения массы тела и способ её получения
|
AU2006275784A1
(en)
|
2005-07-28 |
2007-02-08 |
Reliant Pharmaceuticals, Inc. |
Treatment with dihydropyridine calcium channel blockers and omega-3 fatty acids and a combination product thereof
|
ITMI20051560A1
(it)
|
2005-08-10 |
2007-02-11 |
Tiberio Bruzzese |
Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
|
WO2007022427A2
(en)
|
2005-08-18 |
2007-02-22 |
Accelalox, Inc. |
Methods for bone treatment by modulating an arachidonic acid metabolic or signaling pathway
|
KR100704009B1
(ko)
|
2005-08-30 |
2007-04-04 |
한국화학연구원 |
염증억제 활성을 가지는6-알킬아미노-2-메틸-2'-(n-메틸치환술폰아미도)메틸-2h-1-벤조피란 유도체
|
RU2302248C2
(ru)
|
2005-08-30 |
2007-07-10 |
Федеральное государственное унитарное предприятие Тихоокеанский научно-исследовательский рыбохозяйственный центр |
Средство, обладающее липидкорригирующими, гипокоагуляционными и антиоксидантными свойствами
|
US7405302B2
(en)
|
2005-10-11 |
2008-07-29 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
AU2006304689A1
(en)
|
2005-10-18 |
2007-04-26 |
Aegerion Pharmaceuticals |
Compositions for lowering serum cholesterol and/or triglycerides
|
WO2007050271A2
(en)
|
2005-10-25 |
2007-05-03 |
Wyeth |
5-lipoxygenase modulators
|
WO2007051065A2
(en)
|
2005-10-28 |
2007-05-03 |
Numerate, Inc. |
Compositions and treatments for inhibiting kinase and/or hmg-coa reductase
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
US20070105793A1
(en)
|
2005-11-04 |
2007-05-10 |
Curt Hendrix |
Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease
|
US20070225285A1
(en)
|
2005-11-04 |
2007-09-27 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
US20070219206A1
(en)
|
2005-11-04 |
2007-09-20 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US20070244128A1
(en)
|
2005-11-04 |
2007-10-18 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein (flap) inhibitors
|
US20070104779A1
(en)
|
2005-11-07 |
2007-05-10 |
Rongen Roelof M |
Treatment with omega-3 fatty acids and products thereof
|
CA2628305C
(en)
|
2005-11-11 |
2014-05-06 |
Mochida Pharmaceutical Co., Ltd. |
Jelly composition
|
AU2006315177A1
(en)
|
2005-11-15 |
2007-05-24 |
Baxter Healthcare S.A. |
Compositions of lipoxygenase inhibitors
|
WO2007058523A1
(en)
|
2005-11-17 |
2007-05-24 |
N.V. Nutricia |
Composition with docosapentaenoic acid
|
RU2395280C2
(ru)
|
2005-11-21 |
2010-07-27 |
Тева Фармасьютикл Индастриес Лтд. |
Фармацевтическая лекарственная форма аторвастатина
|
US20070202206A1
(en)
|
2005-11-29 |
2007-08-30 |
Palu Afa K |
Morinda Citrifolia Leaf Juice And Leaf Extract Based Formulations
|
CA2634139C
(en)
|
2005-12-20 |
2015-06-23 |
Cenestra, Llc. |
Omega 3 fatty acid formulations
|
US20070237848A1
(en)
|
2005-12-21 |
2007-10-11 |
Brad Rawson |
MORINDA CITRIFOLIA BASED COMPOSITIONS FOR TREATMENT OF ANTI-INFLAMMATORY DISEASES THROUGH INHIBITION OF COX-1, COX-2, INTERLEUKIN-1beta, INTERLEUKIN-6, TNF-alpha, HLE, AND iNOS
|
DK1800675T3
(da)
|
2005-12-23 |
2011-09-05 |
Nutricia Nv |
Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens
|
EP1973536A2
(en)
|
2006-01-05 |
2008-10-01 |
Reliant Pharmaceuticals, Inc. |
Treatment of fatty liver
|
WO2007087250A2
(en)
|
2006-01-23 |
2007-08-02 |
Amira Pharmaceuticals, Inc. |
Tricyclic inhibitors of 5-lipoxygenase
|
EP1905424A3
(en)
|
2006-02-02 |
2008-04-30 |
Ranbaxy Laboratories Limited |
Process for the preparation of a pharmaceutical composition comprising stabilized statin particles
|
CN101365438A
(zh)
|
2006-02-07 |
2009-02-11 |
持田制药株式会社 |
预防中风复发的组合物
|
JP4005104B2
(ja)
|
2006-02-07 |
2007-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
JP5069448B2
(ja)
|
2006-02-07 |
2012-11-07 |
持田製薬株式会社 |
脳卒中再発予防用組成物
|
CA2642220A1
(en)
|
2006-02-14 |
2007-08-23 |
Intercept Pharmaceuticals, Inc. |
Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
|
CA2642216A1
(en)
|
2006-02-21 |
2007-08-30 |
Critical Therapeutics, Inc. |
New crystal forms and pharmaceutical compositions of (+)-r-zileuton
|
CN101437508A
(zh)
|
2006-03-03 |
2009-05-20 |
孟山都技术有限公司 |
用于改善心血管健康的十八碳四烯酸
|
WO2007103557A2
(en)
|
2006-03-09 |
2007-09-13 |
Reliant Pharmaceuticals, Inc. |
Coating capsules with active pharmaceutical ingredients
|
US8784886B2
(en)
|
2006-03-09 |
2014-07-22 |
GlaxoSmithKline, LLC |
Coating capsules with active pharmaceutical ingredients
|
WO2007128801A1
(en)
|
2006-05-08 |
2007-11-15 |
Novartis Ag |
Combination of organic compounds
|
ES2500063T3
(es)
|
2006-05-31 |
2014-09-29 |
Mochida Pharmaceutical Co., Ltd. |
Composición para prevenir la aparición de acontecimiento cardiovascular en paciente con riesgo múltiple
|
US20090042835A1
(en)
|
2006-06-02 |
2009-02-12 |
Davis Roger A |
Compositions and methods for ameliorating hyperlipidemia
|
WO2007143164A1
(en)
|
2006-06-02 |
2007-12-13 |
San Diego State University Research Foundation |
Compositions and methods for ameliorating hyperlipidemia
|
US20070292501A1
(en)
|
2006-06-05 |
2007-12-20 |
Udell Ronald G |
Chewable soft gelatin capsules
|
JP5658876B2
(ja)
|
2006-07-05 |
2015-01-28 |
フォトンズ コーポレーション リミテッド |
大規模従属栄養培養領域にて産生される超高純度epaと極性脂質
|
US20090304784A1
(en)
|
2006-07-28 |
2009-12-10 |
V. Mane Fils |
Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
|
JP5223177B2
(ja)
|
2006-08-23 |
2013-06-26 |
地方独立行政法人北海道立総合研究機構 |
アルミニウム回収用材料、同材料の製造方法及びアルミニウムの回収方法
|
EP2059241A1
(en)
|
2006-09-05 |
2009-05-20 |
Schering Corporation |
Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
|
US20080085911A1
(en)
|
2006-10-10 |
2008-04-10 |
Reliant Pharmaceuticals, Inc. |
Statin and omega-3 fatty acids for reduction of apo-b levels
|
CN101553221A
(zh)
|
2006-10-10 |
2009-10-07 |
瑞莱恩特医药品有限公司 |
用于降低APO-B水平的抑制素和ω-3脂肪酸
|
JP2010506841A
(ja)
*
|
2006-10-13 |
2010-03-04 |
リライアント・ファーマシューティカルズ・インコーポレイテッド |
抗不整脈薬およびオメガ−3脂肪酸およびそれらの組合せ品による治療法
|
WO2008088415A1
(en)
|
2006-10-18 |
2008-07-24 |
Reliant Pharmaceuticals, Inc. |
Omega-3 fatty acids for reduction of lp-pla2 levels
|
US20080306154A1
(en)
|
2006-11-03 |
2008-12-11 |
My Svensson |
Treatment and prevention of major adverse cardiovascular events or major coronary evens by administering Omega-3 fatty acids
|
US20080125490A1
(en)
*
|
2006-11-03 |
2008-05-29 |
My Svensson |
Treatment and prevention of cardiovascular disease in patients with chronic kidney disease by administering Omega-3 Fatty Acids
|
US20080226758A1
(en)
|
2006-11-28 |
2008-09-18 |
Shixin Deng |
Lipoxygenase and Cyclooxygenase Inhibition
|
US20090042849A1
(en)
|
2006-12-06 |
2009-02-12 |
Yochai Birnbaum |
Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
|
US20080161279A1
(en)
|
2006-12-21 |
2008-07-03 |
Wisler Gerald L |
Methods of Treating Obesity
|
WO2008088030A1
(ja)
|
2007-01-17 |
2008-07-24 |
Mochida Pharmaceutical Co., Ltd. |
血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
|
CA2676485A1
(en)
|
2007-01-23 |
2008-07-31 |
Reddy Us Therapeutics, Inc. |
Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
|
US20080185198A1
(en)
|
2007-02-02 |
2008-08-07 |
Steven Mark Jones |
Next generation hybrid III parallel/series hybrid system
|
US20080249130A1
(en)
|
2007-02-09 |
2008-10-09 |
Sirtris Pharmaceuticals, Inc. |
Gut microsomal triglyceride transport protein inhibitors
|
DK2121576T3
(en)
|
2007-02-15 |
2016-02-15 |
Ct De Rech Sur Les Biotechnologies Marine |
Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof
|
CA2677036A1
(en)
|
2007-03-06 |
2008-09-12 |
Bioriginal Food & Science Corp. |
Soft gelatin capsule shells containing oil soluble flavoring and methods of making the same
|
WO2008115529A1
(en)
|
2007-03-20 |
2008-09-25 |
Reliant Pharmaceuticals, Inc. |
Compositions comprising omega-3 fatty acids and cetp inhibitors
|
US8048880B2
(en)
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
WO2008145170A1
(de)
|
2007-05-31 |
2008-12-04 |
Siemens Aktiengesellschaft |
Verfahren zum konfigurieren einer automatisierungsanlage
|
US20080299187A1
(en)
*
|
2007-06-01 |
2008-12-04 |
Joar Opheim |
Substances for Reducing Occurence of Major Cardiac Events in Humans
|
TW201242961A
(en)
|
2007-06-20 |
2012-11-01 |
Ironwood Pharmaceuticals Inc |
FAAH inhibitors
|
CN102552213A
(zh)
|
2007-06-29 |
2012-07-11 |
武田药品工业株式会社 |
无缝胶囊
|
US20090092595A1
(en)
|
2007-07-13 |
2009-04-09 |
Regents Of The University Of California |
Suppression of sPLA2-integrin binding for treating an inflammatory condition
|
US20090062369A1
(en)
|
2007-08-31 |
2009-03-05 |
Joaquim Trias |
Use of secretory phospholipase a2 (spla2) inhibitors to decrease spla2 levels
|
US8969400B2
(en)
|
2007-10-01 |
2015-03-03 |
Duke University |
Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
|
WO2009085388A2
(en)
|
2007-12-20 |
2009-07-09 |
Abbott Laboratories |
Stable nutritional powder
|
US8361534B2
(en)
|
2007-12-20 |
2013-01-29 |
Abbott Laboratories |
Stable nutritional powder
|
JP5421126B2
(ja)
|
2008-01-10 |
2014-02-19 |
武田薬品工業株式会社 |
カプセル製剤
|
US20090182049A1
(en)
|
2008-01-16 |
2009-07-16 |
Joar Arild Opheim |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
|
MX2010012482A
(es)
|
2008-05-15 |
2010-12-01 |
Pronova Biopharma Norge As |
Proceso para aceite de kril.
|
JPWO2009142242A1
(ja)
|
2008-05-20 |
2011-09-29 |
持田製薬株式会社 |
ハイリスク患者の心血管イベント予防用組成物
|
WO2009151125A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
肝障害の診断及び治療
|
WO2009151116A1
(ja)
|
2008-06-13 |
2009-12-17 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
JPWO2009154230A1
(ja)
|
2008-06-17 |
2011-12-01 |
持田製薬株式会社 |
非アルコール性脂肪肝炎の予防/改善・治療薬
|
JP5922868B2
(ja)
|
2008-07-07 |
2016-05-24 |
持田製薬株式会社 |
脂質異常症の改善または治療薬
|
DK2334295T3
(en)
|
2008-09-02 |
2017-10-09 |
Amarin Pharmaceuticals Ie Ltd |
PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME
|
WO2010038796A1
(ja)
|
2008-09-30 |
2010-04-08 |
持田製薬株式会社 |
C型肝炎治療剤
|
US20100130608A1
(en)
|
2008-10-01 |
2010-05-27 |
Martek Biosciences Corporation |
Compositions and methods for reducing triglyceride levels
|
WO2010080976A1
(en)
|
2009-01-09 |
2010-07-15 |
Sdg, Inc. (An Ohio Corporation) |
Insulin therapies for the treatment of diabetes, diabetes related ailments, and/or diseases or conditions other than diabetes or diabetes related ailments
|
EP2405921A4
(en)
|
2009-01-26 |
2013-05-22 |
Protiva Biotherapeutics Inc |
COMPOSITIONS AND METHODS FOR INACTIVATION OF APOLIPOPROTEIN C-III EXPRESSION
|
LT3037089T
(lt)
|
2009-02-10 |
2020-01-10 |
Amarin Pharmaceuticals Ireland Limited |
Eikozapentaeno rūgšties etilo esteris skirtas hipertriglicidemijai gydydti
|
JP6176894B2
(ja)
|
2009-03-09 |
2017-08-09 |
プロノヴァ・バイオファーマ・ノルゲ・アーエス |
脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用
|
US8241672B2
(en)
|
2009-03-11 |
2012-08-14 |
Stable Solutions Llc |
Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
|
US20120046251A1
(en)
|
2009-04-06 |
2012-02-23 |
The Regents Of The University Of California |
Inhibitors of soluble epoxide hydrolase to inhibit or prevent niacin-induced flushing
|
AU2010241567B2
(en)
|
2009-04-29 |
2013-10-31 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
|
WO2010127103A1
(en)
|
2009-04-29 |
2010-11-04 |
Amarin Pharma, Inc. |
Stable pharmaceutical composition and methods of using same
|
CA2972063C
(en)
|
2009-05-22 |
2019-12-17 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of .omega.3 fatty acid
|
US8455472B2
(en)
|
2009-06-15 |
2013-06-04 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
RU2402326C1
(ru)
|
2009-06-22 |
2010-10-27 |
Учреждение Российской академии медицинских наук Дальневосточный научный центр физиологии и патологии дыхания Сибирского отделения Российской академии медицинских наук (ДНЦ ФПД СО РАМН) |
Способ коррекции инсулинорезистентности при метаболическом синдроме
|
US8557275B2
(en)
|
2009-07-23 |
2013-10-15 |
U.S. Nutraceuticals, LLC |
Composition and method to alleviate joint pain using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA
|
KR101685734B1
(ko)
|
2009-09-01 |
2016-12-12 |
카타베이시스 파마슈티칼즈, 인코포레이티드 |
지방산 나이아신 접합체 및 그의 용도
|
KR101798670B1
(ko)
|
2009-09-23 |
2017-11-16 |
아마린 코포레이션 피엘씨 |
오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법
|
JP5758298B2
(ja)
|
2009-10-16 |
2015-08-05 |
持田製薬株式会社 |
非アルコール性脂肪肝炎関連マーカー
|
EP2488022B1
(en)
|
2009-10-16 |
2018-01-10 |
Mochida Pharmaceutical Co., Ltd. |
Compositions
|
CN102821602B
(zh)
|
2010-01-08 |
2016-04-20 |
凯特贝希制药公司 |
脂肪酸富马酸酯衍生物及其用途
|
WO2011087981A2
(en)
|
2010-01-15 |
2011-07-21 |
E. I. Du Pont De Nemours And Company |
Clinical benefits of eicosapentaenoic acid in humans
|
RU2728825C2
(ru)
|
2010-03-04 |
2020-07-31 |
Амарин Фармасьютикалз Айрлэнд Лимитед (Апил) |
Композиции и способы лечения и/или предотвращения сердечно-сосудистого заболевания
|
US8846321B2
(en)
|
2010-03-12 |
2014-09-30 |
President And Fellows Of Harvard College |
Association of levels of HDL-cholesterol apolipoprotein CIII with the risk of coronary heart disease and cardiovascular events
|
US8663704B2
(en)
|
2010-04-30 |
2014-03-04 |
U.S. Nutraceuticals, LLC |
Composition and method to improve blood lipid profiles and optionally reduce low density lipoprotein (LDL) per-oxidation in humans
|
GB2480146A
(en)
|
2010-05-05 |
2011-11-09 |
St Giles Foods Ltd |
Fruit or vegetable based edible composition comprising nutritional supplement
|
US8609138B2
(en)
|
2010-06-30 |
2013-12-17 |
Mochida Pharmaceutical Co., Ltd. |
ω3 fatty acid compound preparation
|
AR082930A1
(es)
|
2010-09-08 |
2013-01-16 |
Pronova Biopharma Norge As |
Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina
|
US10557856B2
(en)
|
2010-09-24 |
2020-02-11 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Biomarkers of renal injury
|
WO2012054555A2
(en)
|
2010-10-20 |
2012-04-26 |
Glycomark, Inc. |
Improved identification of pre-diabetes using a combination of mean glucose and 1,5-anhydroglucitol markers
|
WO2012063820A1
(ja)
|
2010-11-09 |
2012-05-18 |
持田製薬株式会社 |
血糖値上昇抑制剤
|
NZ727980A
(en)
|
2010-11-29 |
2018-08-31 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
EP2471537A1
(en)
|
2010-12-30 |
2012-07-04 |
PregLem S.A. |
Treatment of pain associated with dislocation of basal endometrium
|
EP2502506A1
(en)
|
2011-03-21 |
2012-09-26 |
Abbott Laboratories |
Methods for improving bone health in infants using long chain polyunsaturated fatty acids
|
KR101310710B1
(ko)
|
2011-03-23 |
2013-09-27 |
한미약품 주식회사 |
오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물
|
US20120264824A1
(en)
|
2011-04-15 |
2012-10-18 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US8660662B2
(en)
|
2011-04-22 |
2014-02-25 |
Medtronic, Inc. |
Low impedance, low modulus wire configurations for a medical device
|
KR20190062511A
(ko)
|
2011-04-27 |
2019-06-05 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지방단백질 ciii (apociii) 발현의 조정
|
WO2013040507A1
(en)
|
2011-09-15 |
2013-03-21 |
Omthera Pharmaceuticals, Inc. |
Methods and compositions for treating, reversing, inhibiting or preventing resistance to antiplatelet therapy
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US20140323709A1
(en)
|
2011-12-12 |
2014-10-30 |
National Cerebral And Cardiovascular Center |
Oligonucleotide and therapeutic agent for hyperlipidemia containing same as active ingredient
|
EP2800469B1
(en)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
|
WO2013136277A1
(en)
|
2012-03-13 |
2013-09-19 |
Unimark Remedies Ltd. |
Pharmaceutical compositions for treatment of cardiovascular diseases
|
MY189576A
(en)
|
2012-03-30 |
2022-02-17 |
Micelle Biopharma Inc |
Omega-3 fatty acid ester compositions
|
JP6173437B2
(ja)
|
2012-05-07 |
2017-08-02 |
オムセラ・ファーマシューティカルズ・インコーポレイテッド |
スタチン及びω−3脂肪酸の組成物
|
US9700538B2
(en)
|
2012-05-15 |
2017-07-11 |
Mochida Pharmaceutical Co., Ltd. |
Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity C-reactive protein
|
EP2854951B1
(de)
|
2012-05-30 |
2016-09-07 |
Clariant International Ltd. |
Zusammensetzung enthaltend aminosäuretenside, betaine und n-methyl-n-acylglucamine mit verbesserter schaumqualität und höherer viskosität
|
US20130324607A1
(en)
|
2012-06-05 |
2013-12-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypercholesterolemia
|
US20140080850A1
(en)
|
2012-06-05 |
2014-03-20 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising an omega-3 fatty acid and a hydroxy-derivative of a statin and methods of using same
|
WO2013185032A1
(en)
|
2012-06-07 |
2013-12-12 |
President And Fellows Of Harvard College |
Nanotherapeutics for drug targeting
|
WO2013192109A1
(en)
|
2012-06-17 |
2013-12-27 |
Matinas Biopharma, Inc. |
Omega-3 pentaenoic acid compositions and methods of use
|
US20140004183A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating cardiovascular disease in statin-tolerant subjects
|
US20150157593A1
(en)
|
2012-06-29 |
2015-06-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing ldl-p
|
US20140005265A1
(en)
|
2012-06-29 |
2014-01-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods for treating hypertriglyceridemia
|
RS61557B1
(sr)
|
2012-06-29 |
2021-04-29 |
Amarin Pharmaceuticals Ie Ltd |
Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline
|
RU2015102808A
(ru)
|
2012-06-29 |
2016-08-20 |
Амарин Фармасьютикалз Айрлэнд Лимитед |
Способы лечения педиатрического метаболического синдрома
|
KR102103426B1
(ko)
|
2012-09-28 |
2020-04-22 |
모치다 세이야쿠 가부시키가이샤 |
당뇨병 신규 발병 저감용 조성물
|
WO2014057522A1
(en)
|
2012-10-12 |
2014-04-17 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
EP2719382A1
(en)
|
2012-10-12 |
2014-04-16 |
Mochida Pharmaceutical Co., Ltd. |
Ethyl Eicosapentanoate and Pharmaceutical Compositions Comprising Ethyl Eicosapentanoate as an Active Ingredient for Use in the Treatment of Non-Alcoholic Steatohepatitis
|
US20140142127A1
(en)
|
2012-10-23 |
2014-05-22 |
Almburg, Llc |
Stable Compositions of HMG-COA Reductase Inhibitors and Omega-3 Oils
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
US8703188B1
(en)
*
|
2012-11-19 |
2014-04-22 |
Azanta A/S |
Dispersible tablet
|
US20140213648A1
(en)
|
2012-12-31 |
2014-07-31 |
Amarin Pharmaceuticals Ireland Limited |
Methods of increasing epa blood levels
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
US20140221452A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and 5-htp and methods of use thereof
|
US20140221676A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating and/or preventing cardiovascular disease
|
US20140221358A1
(en)
|
2013-02-06 |
2014-08-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and diazoxide and methods of use thereof
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
US20140242216A1
(en)
|
2013-02-24 |
2014-08-28 |
Mead Johnson Nutrition Company |
Amino Acid And Protein Hydrolysate Based Formulas With A Stable Emulsion System
|
US20140249214A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of warfarin and ethyl eicosapentaenoate
|
US20140249220A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for reducing a fatty acid desaturation index in a subject in need thereof
|
US20140249200A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
|
US20140249225A1
(en)
|
2013-03-01 |
2014-09-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US9661874B2
(en)
|
2013-03-11 |
2017-05-30 |
Mead Johnson Nutrition Company |
Nutritional compositions containing structured fat globules and uses thereof
|
US20140255537A1
(en)
|
2013-03-11 |
2014-09-11 |
Mead Johnson Nutrition Company |
Nutritional Compositions Containing an Enriched Lipid Fraction and Uses Thereof
|
US20140271907A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and krill oil and methods of use thereof
|
US20140275252A1
(en)
|
2013-03-14 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating traumatic brain injury
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
US10441560B2
(en)
|
2013-03-15 |
2019-10-15 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
SG11201507288UA
(en)
|
2013-03-15 |
2015-10-29 |
Mochida Pharm Co Ltd |
Compositions and methods for treating non-alcoholic steatohepatitis
|
WO2014179325A1
(en)
|
2013-04-29 |
2014-11-06 |
Matinas Biopharma, Inc. |
Omega-3 fatty acid formulations for use as pharmaceutical treatment
|
KR102240429B1
(ko)
|
2013-05-06 |
2021-04-15 |
한미약품 주식회사 |
로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
|
US20140357717A1
(en)
|
2013-06-04 |
2014-12-04 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
DK3003038T3
(da)
|
2013-06-07 |
2019-11-11 |
Scripps Research Inst |
2h-1,2,3-triazolderivater som inhibitorer af fibrose
|
WO2014205310A2
(en)
|
2013-06-21 |
2014-12-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Techniques for predicting cardiac arrhythmias based on signals from leads of electrocardiography
|
CA2918336C
(en)
|
2013-07-18 |
2022-05-24 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of .omega.3 fatty acid
|
EP3023099B1
(en)
|
2013-07-18 |
2020-09-30 |
Mochida Pharmaceutical Co., Ltd. |
Self-emulsifying composition of -3 fatty acid
|
WO2015021141A1
(en)
|
2013-08-06 |
2015-02-12 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder in a subject on apo-c3 modulating therapy
|
US20150051282A1
(en)
|
2013-08-14 |
2015-02-19 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating a cardiovascular disorder and/or joint pain in a subject on glucosamine therapy
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
US20150073050A1
(en)
|
2013-09-09 |
2015-03-12 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of omeprazole and eicosapentaenoic acid or a derivative thereof
|
US20160213639A1
(en)
|
2013-10-07 |
2016-07-28 |
Mochida Pharmaceutical Co., Ltd. |
Compositions and methods for treating non-alcoholic steatohepatitis
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
WO2015066512A1
(en)
|
2013-10-31 |
2015-05-07 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
WO2015157697A1
(en)
|
2014-04-11 |
2015-10-15 |
Cymabay Therapeutics, Inc. |
Treatment of nafld and nash
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
US10172818B2
(en)
|
2014-06-16 |
2019-01-08 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
US20170213648A1
(en)
|
2014-08-01 |
2017-07-27 |
Western Michigan University Research Foundation |
Self-supported electronic devices
|
CN107405326B
(zh)
|
2015-01-21 |
2021-06-15 |
持田制药株式会社 |
ω3脂肪酸的自乳化组合物
|
CN107427484A
(zh)
|
2015-01-21 |
2017-12-01 |
持田制药株式会社 |
ω3脂肪酸的自乳化组合物
|
WO2016140949A1
(en)
|
2015-03-02 |
2016-09-09 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidative modification of membrane polyunsaturated fatty acids
|
US20170151202A1
(en)
|
2015-09-09 |
2017-06-01 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
EP3275438B2
(en)
|
2016-07-29 |
2023-09-13 |
Kowa Company, Ltd. |
Methods of preventing cardiovascular events in residual risk dyslipidemic populations
|
US11197870B2
(en)
|
2016-11-10 |
2021-12-14 |
Galmed Research And Development Ltd |
Treatment for hepatic fibrosis
|
US10966951B2
(en)
|
2017-05-19 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
US20190054058A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of Treating or Preventing Bone Loss
|
US20190054054A1
(en)
|
2017-08-15 |
2019-02-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods reducing or preventing oxidation of high density lipoprotein (HDL)
|
US20190209506A1
(en)
|
2018-01-09 |
2019-07-11 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of ldl or lipid membranes in a subject in need thereof
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
US20190275057A1
(en)
|
2018-03-06 |
2019-09-12 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and Methods for Lowering Triglycerides in a Subject with Reduced Kidney Function and Diabetes Mellitus
|
WO2020037153A1
(en)
|
2018-08-17 |
2020-02-20 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
|
WO2020068163A1
(en)
*
|
2018-09-24 |
2020-04-02 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject
|
KR20210066831A
(ko)
|
2018-09-26 |
2021-06-07 |
애머린 파마슈티칼스 아일랜드 리미티드 |
공기 오염에 대한 노출에 의해 생긴 질환 및/또는 장애의 치료 또는 예방을 위한 조성물 및 방법
|
US20200261391A1
(en)
|
2019-02-15 |
2020-08-20 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a statin-treated subject by increasing serum and plasma epa and dpa levels
|
JP2022542513A
(ja)
|
2019-08-01 |
2022-10-04 |
エボニック オペレーションズ ゲーエムベーハー |
ω-3脂肪酸塩とボスウェリア種由来のガム樹脂の抽出物とを含む調製物
|
JP2022554020A
(ja)
|
2019-11-12 |
2022-12-27 |
アマリン ファーマシューティカルズ アイルランド リミテッド |
心房細動および/または心房粗動を患う対象における心血管イベントのリスクを低減する方法
|